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CHAPTER 1: OVERCOMING THE CONCENTRATION DEPENDENCE OF
RESPONSIVE CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING
Parts of this chapter were adapted with permission from Ekanger, L. A.; Allen, M. J.
Metallomics, 2015, 7, 405. Reproduced by permission of The Royal Society of Chemistry.
Introduction
This chapter describes strategies used to design responsive contrast agents that are
concentration-independent. Strategies to overcome concentration-dependent responsive contrast
agents are relevant to this thesis because EuII-containing complexes offer a platform for
concentration-independent responsive imaging. Responsive contrast agents have been discussed
elsewhere,1–20 but this chapter focuses on overcoming concentration-dependence in responsive
contrast agents for magnetic resonance imaging (MRI). Specifically, this chapter discusses
strategies that complement the depth penetration of MRI, including ratiometric chemical
exchange saturation transfer, ratiometric relaxation rates, dual-mode imaging, dual-injection, and
ligand field induced chemical shift strategies from the year 2000 to present.
The responsive contrast agents discussed in this chapter have been designed for MRI.
MRI is a staple of modern diagnostic medicine and preclinical research because of its noninvasive nature and exquisite spatial resolution (0.025 mm isotropic resolution in preclinical
scans).21 The contrast-to-noise ratio of MRI scans can be enhanced with the use of exogenous
molecules called contrast agents, often paramagnetic compounds, that interact with nearby nuclei
(1H is the most commonly detected), resulting in darker or brighter pixels in an image. The
intensity of pixels in a conventional MRI image correlates to the amount of time—longitudinal
(T1), transverse (T2), or both—needed for the nuclear dipoles of protons to realign with the
external magnetic field (generated by the scanner) after the nuclear dipoles have been misaligned
by a radiofrequency pulse (also generated by the scanner). Paramagnetic contrast agents,
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endowed with their own local magnetic field, can catalytically expedite the realignment, or
relaxation, by interacting with numerous water protons through the exchange of water molecules
or protons. Every contrast agent, even if structurally similar, produces contrast to different
extents in MRI, and the behavior of paramagnetic contrast agents has been modeled and
understood through the modified Solomon–Bloembergen–Morgan theory.22–24 With the
predictive power of this theory, chemists have performed a great deal of research with the goal of
optimizing contrast agent efficiency [longitudinal (r1) or transverse (r2) relaxivity],25–32 which is
a measure of the ability to relax protons as a function of the concentration of a contrast agent.
Accordingly, the enhanced relaxation time brought about by a contrast agent is inherently
dependent upon the concentration of a contrast agent. This dependence is one of the major
limitations of contrast agents that change in response to specific stimuli.
Some of the earliest efforts toward developing responsive MRI contrast agents revolved
around protein binding, which often caused relatively large increases in relaxivity. 23 The first
reported enzyme-responsive contrast agent, the galactopyranose-functionalized gadolinium(III)containing complex 1.1 (Figure 1.1), was introduced by Meade and co-workers and responded to
the presence of β-galactosidase to form 1.2 with a 20% increase in r1.33,34 In a separate report
using 1.3 (Figure 1.1), the same group observed a 77% change (3.26 to 5.76 mM–1 s–1) in r1 in
response to changes in the concentration of calcium ions resulting in the formation of 1.4.35,36
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Figure 1.1. A. The first responsive contrast agent. In the presence of β-galactosidase, a galactose
unit is removed from the contrast agent to facilitate the coordination of a water molecule and,
consequently, a change in contrast enhancement;33,34 B. A contrast agent (1.3 to 1.4) that
responds to changes in the concentration of calcium ions.35,36
Since these seminal reports, many other responsive contrast agents for MRI have been
developed that respond to a wide range of stimuli including changes in pH,37–58 temperature,57–62
metal ion concentration,35,36,63–65 and redox-active species.66–73 Many responsive contrast agents
are designed with the goal of improving diagnostic capabilities in vivo. When performing in vivo
imaging, however, the response of a contrast agent is meaningful only when the concentration of
the contrast agent is known. To illustrate this point, the relaxivities of 1.3 and 1.4 have been
plotted to exemplify the differences between in vitro (Figure 1.2) and in vivo (Figure 1.3)
experiments. For in vitro experiments, the concentration of the contrast agent can easily be
determined; therefore, the readout of 1/T1 can be used to determine if a contrast agent has
responded. With in vivo studies, the concentration of contrast agents cannot be easily
determined; therefore, when 1/T1 is measured during the imaging experiment, it is currently
impossible to differentiate between a complete response, no response, or a partial response. This
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concentration-dependent nature holds true for many responsive contrast agents that have not
been specifically designed to address the issue of concentration-dependence.

Figure 1.2. The relaxivities of 1.3 and 1.4 are the slopes of the lines of the paramagnetic
contribution to relaxation rate (1/T1P) as a function of the concentration of contrast agent. The
plots illustrate the relaxivity in the presence (1.4, 5.76 mM–1 s–1) and absence (1.3, 3.26 mM–1 s–
1
) of calcium ions.35,36 Relaxivity (slope of a linear function) can be expressed as an equation in
the form of 1/T1P = r1x + b (in this example b = 0 because only the paramagnetic contribution is
being plotted), where r1 is the relaxivity or slope of the line and x is the concentration of the
contrast agent. When calcium is present, the concentrations of 1.3 and 1.4 can be expressed as
x1.3 and x1.4, and the linear equation becomes 1/T1P = (r11.3)x1.3 + (r11.4)x1.4. The vertical dashed
line is a visual guide to demonstrate that a known concentration of contrast agent (in this
example 0.60 mM was arbitrarily selected) permits 1/T1P measurements (horizontal dashed lines)
to indicate the absence (2.0 s–1) or presence (3.5 s–1) of calcium. When the initial concentration
of contrast agent is known (0.60 mM), the total concentration will remain 0.60 mM because the
volume of a sample (in vitro) is constant. Accordingly, the total concentration of contrast agent
bound to calcium can be expressed as x1.4 = 0.60 mM – x1.3. Substituting for x1.4 in 1/T1P =
(r11.3)x1.3 + (r11.4)x1.4 yields 1/T1P = (r11.3)x1.3 + (r11.4)(0.60 mM – x1.3), which is solvable because
there is one equation and one variable. In this example, the 1/T1P values for 1.3 and 1.4 are
boundaries, and the actual value can fall anywhere between the two boundaries. However, the
1/T1P equation is solvable even for incomplete conversions between 1.3 and 1.4.
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Figure 1.3. The relaxivities of 1.3 and 1.4 plotted as in Figure 1.2, where 1/T1P = (r11.3)x1.3 +
(r11.4)x1.4. The horizontal dashed line is a visual guide to demonstrate that a measured 1/T1P value
(in this example 2.0 s–1 was arbitrarily selected) can be produced by a 0.6 mM solution of 1.3, a
lower concentration of 1.4, or a mixture of 1.3 and 1.4. Without knowing the concentration of at
least one of the contrast agents or the total amount of the two agents, the equation for 1/T1P
contains two unknown variables (x1.3 and x1.4) and, consequently, cannot be solved.
1.1 Chemical Exchange Saturation Transfer
1.1.1 Ratiometric Chemical Exchange Saturation Transfer
In contrast-enhanced T1-weighted MRI, contrast agents influence the relaxation times of
nearby protons. The process is catalytic because of the relatively fast rate of exchange between
coordinated and bulk water protons, resulting in interactions with a large number of protons in a
short period of time. If, however, a contrast agent alters the chemical shift of exchanging protons
such that the shift is distinguishable from the proton resonance of bulk water, a different
mechanism of contrast can be generated. By selectively saturating the chemically-shifted protons
with a radiofrequency pulse, the intensity of the signals from these protons are diminished.
During the saturation event, the shifted protons continue to exchange with bulk water through
water or proton exchange. The net result is a transfer of nuclear dipole saturation to the bulk
water signal, which causes a reduction in intensity (Figure 1.4) that is used to generate an image.
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Figure 1.4. A simplified representation of chemical exchange saturation transfer (CEST) viewed
as a 1H-NMR spectrum. The signal from an exchangeable proton that is different from bulk
water is reduced via a selective radiofrequency pulse while the proton is exchanging with protons
in the bulk water. The combination of these two events results in a reduction of the signal
intensity from bulk water, which can be measured and expressed as a percent decrease.
The reduction in bulk water signal intensity can be predicted by Eq 1.1 (under the
assumption that saturation time is long enough for an equilibrium to be established),74,75 where
MS is the bulk water signal intensity after radiofrequency saturation at a given frequency, MO is
the bulk water signal intensity in the absence of a radiofrequency pulse, k1 is the pseudo firstorder proton exchange rate, and T1W is the longitudinal relaxation time of bulk water. This
contrast mechanism is called chemical exchange saturation transfer (CEST). One of the benefits
of CEST is the ability to influence contrast upon demand, which is possible because CEST can
only be measured after a selective, intentionally applied radiofrequency pulse. The ability to
produce contrast upon demand is not possible with most other contrast agent modalities. Even
with this benefit, the CEST effect is still dependent upon contrast agent concentration as seen in
Eq 1.2,74 where n is the number of exchange sites on the contrast agent, kCA is the proton
exchange rate constant, and [CA] is the concentration of contrast agent. The issue of
concentration was circumvented for pH detection by Balaban and co-workers by using either the
ratio of two different proton-exchange sites on 1.5 or exchange sites on two molecules, 1.6 and
1.7, in the same solution (Figure 1.5).74 The key to this ratiometric method was that each proton-

7

exchange site had a unique pH dependence, which was determined by pKa values. Two unique
exchange sites with non-equivalent pH dependence produce two distinct CEST signals, and the
decrease in bulk water signal intensity for each site can be predicted with Eq 1.3 and Eq 1.4,74
where S1 and S2 denote the first and second exchange sites. A ratio of the two CEST effects (the
quotient of Eq 3 and Eq 4) yields Eq 5.

Figure 1.5. Structures of 5,6-dihydrouracil (1.5), 5-hydroxytryptophan (1.6), and 2imidazolidinethione (1.7) used to demonstrate the first ratiometric CEST response to pH.74
Eq 1.1

𝑀𝑆 /𝑀𝑂 = (1 + 𝑘1 𝑇1𝑊 )–1

Eq 1.2

𝑘1 = [CA]𝑛𝑘CA

Eq 1.3

S1
[(𝑀𝑂 – 𝑀𝑆 )/𝑀𝑆 ]S1 = [CA]S1 𝑛S1 𝑘CA
𝑇1𝑊

Eq 1.4
Eq 1.5

[

𝑀𝑂 – 𝑀𝑆
MS

S2

]

S2
= [CA]S2 𝑛S2 𝑘CA
𝑇1𝑊

[(𝑴𝑶 – 𝑴𝑺 )/𝑴𝑺 ]𝐒𝟏
[(𝑴𝑶 – 𝑴𝑺 )/𝑴𝑺

]𝐒𝟐

=

[𝐂𝐀]𝐒𝟏 𝒏𝐒𝟏 𝒌𝐒𝟏
𝐂𝐀
[𝐂𝐀]𝐒𝟐 𝒏𝐒𝟐 𝒌𝐒𝟐
𝐂𝐀

If the two exchange sites reside on separate molecules, knowledge of the concentration of
the two molecules is still required because they cannot necessarily be assumed to be equal.
However, if both exchange sites reside within the same molecule, the concentration cancels out
on the right side of Eq 5, thus circumventing the requirement of knowing concentration. With
unique pH dependencies, calibrated ratios of CEST effects were used to determine the pH of a
solution without knowledge of concentration. Soon after the initial report of the ratiometric
CEST technique, other groups designed ratiometric CEST contrast agents that incorporated LnIII
ions to induce large chemical shifts.45–47,59
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1.1.2 Ratiometric CEST with Paramagnetic Compounds
Often, the more a CEST signal is shifted downfield or upfield from bulk water, the more
suitable it is for in vivo imaging. This idea is based on magnetization transfer effects that occur in
vivo between bulk water and macromolecules (for example phospholipid membranes and
proteins), which tend to broaden the in vivo bulk water signal.76 Therefore, if CEST signals
within this range are used, the contrast they provide can be drastically reduced or undetectable
due to the magnetization transfer effects that occur during in vivo experiments. Recently, this
notion has been challenged by reports of in vivo CEST imaging using saturation frequencies as
close as 0.8 ppm from bulk water.77 Nevertheless, the development of many CEST agents has
proceeded with the aim of pushing the chemical shift of exchangeable protons far from the bulk
water proton signal. A separate reason for using CEST agents with relatively large chemical
shifts is that the CEST effect is only observable when the chemical shift difference between
chemically shifted and bulk water protons is greater than the proton-exchange rate. Accordingly,
large chemical shifts tend to ensure that this requirement is met and allow contrast agents with
relatively fast exchange rates to be used. To achieve large chemical shift offsets, lanthanide ions
are routinely incorporated into contrast agents because of their ability to alter chemical shifts.78,79
Interestingly, the ground state of EuIII (7F0) does not have a magnetic moment and is
diamagnetic despite having six unpaired f-electrons. However, some excited states are thermally
accessible at room temperature (average magnetic moment ≈ 3.5 Bohr magnetons).80 This
thermally accessible paramagnetic behavior along with luminescent properties that allow for
characterization of coordination environment, are at least two reasons why EuIII has been used in
the design of CEST contrast agents.81–83 Using a EuIII-containing contrast agent, Sherry and coworkers were able to observe the bound water protons on the DOTA-tetra(amide) derivative 1.8
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(Figure 1.6) at ambient temperatures shifted 50 ppm downfield from bulk water.84 Observing the
bound-water proton resonance in an aqueous solution was significant because previously Lnbound water protons had only been observed on a Eu III-containing complex in deuterated
acetonitrile.85 The ability to observe the bound-water resonance was recognized by Aime and coworkers as a step towards ratiometric CEST. Accordingly, Aime and co-workers hypothesized
that the ability to detect both sets of protons (bound-water and amide) of Ln-tetra(amide)
complexes would allow for a ratiometric CEST response that would be independent of the
concentration of the contrast agent using the identical logic exploited by Balaban and co-workers
in Eq 1.6. Furthermore, LnIII-containing complexes would increase the chemical shifts of both
the bound water and amide protons to decrease or eliminate overlap with the broadened bulk
water signal caused by magnetization transfer effects in vivo. Accordingly, Aime and co-workers
investigated DOTA-tetra(amide) derivatives 1.9 through 1.14 to characterize the bulk water and
amide proton resonances.45 Each complex displayed a unique amide proton chemical shift, but
the complexes with the largest chemical shifts did not exhibit the most efficient saturation
transfer because of differences in the longitudinal relaxation time of coordinated water protons.

Figure 1.6. Structures of LnDOTA-tetra(amide) complexes.45–47,84

10

Eq 1.6

[(𝑴𝑶 – 𝑴𝑺 )/𝑴𝑶 ]𝐘𝐛𝐋
[(𝑴𝑶 – 𝑴𝑺 )/𝑴𝑶 ]𝐄𝐮𝐋

=

𝟒[𝐘𝐛𝐋]𝒌𝐘𝐛𝐋
𝐍𝐇
𝟐[𝐄𝐮𝐋]𝒌𝐄𝐮𝐋
𝐇 𝐎
𝟐

Interestingly, in Aime’s study, 1.14 had the highest saturation transfer at 70% despite
only shifting the amide proton signal 16 ppm upfield from bulk water.45 Some lanthanides
revealed an increase in saturation transfer (Figure 1.7) despite relatively small chemical shifts
from bulk water. This phenomenon was attributed to different longitudinal proton relaxation
times for each complex.45 With longer proton relaxation times, saturation transfer occurs to
greater extents than with shorter times. Conversely, rapidly relaxing protons do not have enough
time to transfer saturation to the bulk water proton pool. A striking example of this phenomenon
was observed with 1.10, where the complex shifted amide protons 77 ppm downfield from bulk
water, but the relatively short longitudinal relaxation time of the metal complex caused the
protons near DyIII to relax too quickly for saturation transfer to be observed (Figure 1.7).45
Taken together, it is a prime example that greater chemical shifts do not necessarily equate to
greater CEST properties.

Figure 1.7. Percent saturation transfer as a function of radiofrequency irradiation time at the
same saturation power (B1 = 25 µT) for 1.10 (30 mM,▼), 1.11 (30 mM, ▲), 1.12 (40 mM, ♦),
1.13 (40 mM, ), and 1.14 (30 mM, ■) at 7 T, 312 K, and pH 8.1. Figure adapted with
permission from Paramagnetic Lanthanide(III) Complexes as pH-Sensitive Chemical Exchange
Saturation Transfer (CEST) Contrast Agents for MRI Applications/S. Aime, A. Barge, D. D.
Castelli, F. Fedeli, A. Mortillaro, F. U. Nielsen and E. Terreno/Magn. Reson. Med., 47/4.
Copyright © 2002 Wiley-Liss, Inc.
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Aime and co-workers followed their initial report with an investigation of 1.9, 1.15, and
1.16 to explore and, in the case of 1.9, reinvestigate the relevant characteristics for singlemolecule ratiometric CEST.46 They found that each complex had observable amide and
coordinated water protons that were capable of transferring saturation to bulk water, indicating
that each complex could be used for single-molecule ratiometric CEST. The amide and
coordinated water proton resonances at pH 7 from both studies are listed in Table 1.1, and the
pH-dependence of saturation transfer can be seen in Figure 1.8. The saturation transfer of amide
protons was affected by changes in solution pH; whereas, the saturation transfer of bound water
protons was unaffected in the pH range of 5.5 to 7.5. Accordingly, 1.9, 1.15, and 1.16 were
capable of reporting the pH of a solution without knowledge of contrast agent concentration
using single-molecule ratiometric CEST. The sensitivity, however, was vastly different upon
moving from low to high atomic numbers across the lanthanide series (Figure 1.8). Specifically,
1.15 had the largest and most sensitive ratiometric CEST ratio, and 1.9 had the least sensitive
ratio. This phenomenon is reminiscent of the saturation transfer trend of 1.9 through 1.14, where
longitudinal proton relaxation time was attributed to the observed differences in saturation
transfer regardless of the magnitude of the chemical shifts. Aime and co-workers performed
additional characterization of the properties relevant to single-molecule ratiometric CEST using
LnDOTA-tetra(amide) complexes, which included a demonstration of a ratiometric temperature
response that was independent of contrast agent concentration using 1.15 for in vitro studies.47
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Table 1.1. Amide and bound water proton chemical shifts relative to bulk water of LnDOTAtetra(amide) complexes at pH 7. Both values are required for single-molecule ratiometric CEST.
Compound LnIII

Amide 1H (ppm)

Bound H2O 1H (ppm)

Ref.

1.15

PrIII

13

–70

46,47

1.16

NdIII

11

–50

46,47

1.9

EuIII

–4

40

45

1.10

DyIII

77

not observed

45

1.11

HoIII

39

not observed

45

1.12

ErIII

–22

not observed

45

1.13

TmIII

–51

not observed

45

1.14

YbIII

–16

not observed

45

Figure 1.8. Saturation transfer (ST) as a function of pH for protons of amides (filled symbols)
and coordinated water molecules (open symbols) for 1.9 (circles), 1.15 (triangles), and 1.16
(squares) at 7 T and 312 K after a 4 s irradiation. Figure adapted with permission from Novel
pH-Reporter MRI Contrast Agents, S. Aime, D. D. Castelli and E. Terreno/Angew. Chem.,
114/22. Copyright © 2002 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
In vivo ratiometric CEST imaging of pH was reported by Pagel and co-workers using
1.17 (Figure 1.9).48 After characterizing a concentration-independent pH response of 1.17 using
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ratiometric CEST of the amide and amine protons, they injected 1.17 directly into a tumor within
a mouse. Using a minimum CEST threshold of 2% (corresponding to a 95% probability of the
CEST effect being attributable to 1.17), an in vivo pH map was generated using the ratio of
CEST effects after presaturation at 8 ppm downfield and 11 ppm upfield of bulk water.48 The
frequency offset of these CEST signals was serendipitous because magnetization transfer effects
were thought to affect both signals equally because they are nearly symmetric about the bulk
water signal. However, in vivo ratiometric imaging might be complicated using a signal shifted
relatively close to water and a second signal shifted relatively far from bulk water. This
complication might arise if magnetization transfer effects influence one of the signals to a greater
extent than the other.

Figure 1.9. Structure of 1.17 used for pH and nitric oxide detection. The YbIII-containing
product of the nitric oxide and oxygen reaction is 1.18.48,72
As evidenced through every example highlighted so far, pH is an intuitive target for
responsive contrast agents because protons can be directly imaged with relatively high spatial
resolution with MRI, and contrast agents can be readily designed with proton-exchange sites.
Measuring pH with contrast agents relies on proton exchange because protons associated with
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the contrast agent must exchange with bulk water protons to generate contrast. Proton exchange
is temperature-dependent and, consequently, pH measurements are inherently temperaturedependent. Sherry and co-workers developed single-molecule CEST temperature response
without the use of ratiometric measurements.59 Instead, they recognized that proton exchange is
highly temperature-dependent and that small changes in the exchangeable proton chemical shift
(hyperfine shifts) had the potential to report temperature using MRI. By measuring the boundwater proton exchange for 1.19 (Figure 1.10), they observed a drastic hyperfine shift from 800
to 650 ppm upfield from bulk water within a temperature range of 20 to 50 °C, while 1.9
exhibited smaller hyperfine shifts ranging from 55 to 45 ppm downfield of bulk water within the
same temperature range. Sherry and co-workers chose 1.9 to demonstrate the temperature
response in MRI (Figure 1.11), where the temporal resolution was about 3 min per experiment
for each temperature.

Figure 1.10. Structure of 1.19 investigated for concentration-independent temperature
response.59

Figure 1.11. In vitro temperature maps (1 cm tube diameter) of a solution containing 1.9 (10
mM) at pH 7.0 with a calibrated color bar on the far right. Tair is the temperature of air flowing
over the sample. Reprinted with permission from S. Zhang, C. R. Malloy and A. D. Sherry, J.
Am. Chem. Soc., 2005, 127, 17572. Copyright 2005 American Chemical Society.
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Aime and co-workers combined pH and temperature response in dual-response contrast
agent 1.20 (Figure 1.12), which, like other cyclen-based macrocyclic complexes that contain
chiral centers, exists as a distribution of stereoisomers in solution.58 Only two of the eight
isomeric forms (see Figure 1.13 for all isomers) were observable through
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H-NMR

spectroscopy, and they were assigned as the R and S forms of one conformer. The hydroxyl
protons of the two observable isomers of 1.20 occurred at 99 and 71 ppm downfield from bulk
water. The ratio of the CEST effect for each isomer was used for ratiometric pH measurements
(Figure 1.14) that were independent of the concentration of contrast agent. Additionally, the
hyperfine shifts of each isomer responded linearly with temperature such that both shifts could
individually report the solution temperature without knowledge of contrast agent concentration.
As previously mentioned, temperature affects ratiometric CEST measurements of pH
because proton exchange is inherently temperature-dependent. The case is not so clear for using
changes in hyperfine shift to measure temperature without a pH-dependence because protonation
and deprotonation of functional groups on a complex can potentially alter chemical and
conformational structure of the complex and lead to measurable changes in chemical shifts. It
should be noted that a potential limitation with measuring hyperfine shifts for both of the
previous examples is that multiple CEST images are required to scan a particular frequency
range, which can increase total acquisition time. Longer MRI acquisition times are potentially
limiting because the contrast agent is allowed more time to diffuse.
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Figure 1.12. Structure of 1.20 used for concentration-independent detection of pH and
temperature.58

Figure 1.13. Twisted-square antiprism (TSAP) and square antiprism (SAP) isomeric forms of
LnHPDO3A related to one another either through arm rotation or ring inversion. The bottom
chart demonstrates eight possible isomers. Figure adapted with permission from Yb III-HPDO3A:
A Dual pH- and Temperature-Responsive CEST Agent/D. D. Castelli, E. Terreno and S.
Aime/Angew. Chem. Int. Ed., 50/8. Copyright © 2011 WILEY-VCH Verlag GmbH & Co.
KGaA, Weinheim.
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Figure 1.14. Ratiometric CEST values (calculated using the ratio of the CEST effect of each
isomer) as a function of pH at 20 (■) and 37 °C (). Error bars represent the standard deviation
from the mean. Figure adapted with permission from YbIII-HPDO3A: A Dual pH- and
Temperature-Responsive CEST Agent/D. D. Castelli, E. Terreno and S. Aime/Angew. Chem. Int.
Ed., 50/8. Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Recently, Bartha and co-workers demonstrated a dual pH and temperature response in
vivo that was independent of contrast agent concentration using 1.21 (Figure 1.15).57 They
argued that using single-molecule ratiometric CEST is limited by the assumption that in vivo
magnetization transfer effects will remain constant during the two separate CEST experiments.
The assumption might be invalid when two different radiofrequency saturation powers are used.
Using two saturation powers might cause magnetization transfer effects to be different from one
anatomical region to the next, potentially altering the saturation transfer measurements. To
circumvent this issue of heterogeneous magnetization transfer effects, they proposed using a
magnetization transfer ratio asymmetry (MTRasym) analysis to determine pH.
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Figure 1.15. Structure of 1.21 used for dual pH and temperature response that was independent
of the concentration of contrast agent.57
MTRasym is a plot used to reveal asymmetric features in a CEST spectrum and is
particularly useful for CEST signals that partially overlap with bulk water or endogenous tissue
signal. The MTRasym plot is generated by obtaining the difference in bulk water signal intensity
at equal but opposite frequency offsets from bulk water. The net effect of this analysis is to
remove the baseline saturation transfer to obtain a signal that corresponds to only one exchange
site, allowing the linewidth of the CEST signal to be measured without interference from direct
saturation of either bulk water protons or saturation transfer from endogenous tissues.
Accordingly, Bartha and co-workers measured the MTRasym linewidth of an amide CEST signal
at 45 ppm upfield from bulk water using 1.21 and observed pH dependence from 6 to 8.57
Expectedly, the linewidth was also temperature-dependent because it is a function of exchange
rate, but temperature was found to only influence linewidth between pH 7.5 and 8 at
temperatures above 37 °C. Many disease states coincide with pH values below 7, so the
temperature dependence of linewidth was not considered a barrier to in vivo imaging. As seen in
previous studies by other groups,58,59 the hyperfine shift varied with temperature to allow for
accurate temperature measurements. Importantly, neither the MTRasym linewidth nor the
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hyperfine shift of the signal were concentration-dependent. A pH electrode was used to
standardize the contrast agent response to pH prior to in vivo imaging. Using the aforementioned
techniques, Bartha and co-workers successfully imaged in vivo pH and temperature using a
single molecule (Figure 1.16) with average pH and temperature values of 7.2 ± 0.2 and 37.4 ±
0.5 °C.57 It should be noted that error within the in vivo CEST spectra were not reported. Similar
to measuring hyperfine shifts, a limitation to the MTRasym linewidth approach is that numerous
frequency offset images are required to obtain enough data points to measure the linewidth, and
acquiring more CEST images can substantially increase total acquisition time.

Figure 1.16. (a) CEST spectra of a mouse leg muscle generated pre- (solid line) and postinjection (dashed line) with MTRasym (bottom left) post-injection at 45 ppm upfield from bulk
water. Solid and dashed lines were generated using a tenth-order polynomial; (b) pH map
superimposed onto a pre-injection image of the mouse leg muscle; and (c) temperature map
superimposed onto a pre-injection image. Colored pixels represent regions exhibiting CEST
contrast at ≥95% probability. Figure adapted with permission from Simultaneous In vivo pH and
Temperature Mapping Using a PARACEST-MRI Contrast Agent/N. McVicar, A. X. Li, M.
Suchý, R. H. E. Hudson, R. S. Menon and R. Bartha/Magn. Reson. Med., 70/4. Copyright ©
2012 Wiley Periodicals, Inc.
While lanthanides have been

extensively used for

concentration-independent

measurements of pH, work by Morrow and co-workers has developed the use of d-block metals
for the same purpose.49 Using 1.22 (Figure 1.17) with CoII, four unique amide resonances (112,
95, 54, and 45 ppm) were observed downfield of bulk water in the CEST spectrum. The four
resonances were thought to be caused by two bound amide arms that are not related by
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symmetry. Interestingly, two of the amide resonances were found to have unique pH
dependencies, which made them prime candidates for ratiometric pH response. Using the two
most downfield signals at 112 and 95 ppm, a linear relationship with pH was observed (Figure
18). The ratiometric pH response was not demonstrated to be independent of contrast agent
concentration, but it was observed that the magnitude of CEST (not the ratio) was dependent on
contrast agent concentration.

Figure 1.17. Structure of ligand 1.22 used for ratiometric pH detection with CoII.49

Figure 1.18. CEST ratio as a function of pH using the CoII-containing complex of 1.22 (4 mM)
in 2-(N-morpholino)ethanesulfonic acid or 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
buffer (20 mM) with NaCl (100 mM). Measurements were recorded at 4.7 T and 37 °C. Error
bars represent standard deviations of three measurements. Adapted from Ref. 49 with permission
from The Royal Society of Chemistry.
As demonstrated through the highlighted examples in this section, significant progress
has been made in concentration-independent imaging of pH and temperature. The choice of both
pH and temperature responses can be explained by the ease of detecting protons in MRI and the
inherent temperature-dependence of proton exchange. Although these two parameters were a
good starting point, they are not the only important targets for concentration-independent
response. For example, Pagel and co-workers made progress toward new targets for
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concentration-independent response by demonstrating nitric oxide response in the presence of
oxygen using 1.17,72 which underwent an irreversible reaction forming a triazene linkage
between two equivalents of the contrast agent to form 1.18 (Figure 1.9).72 The measurements
made by Pagel and co-workers using 1.17 and 1.18 were not deemed concentration independent,
but the covalent incorporation of a secondary CEST agent that does not react with nitric oxide,
such as 1.13, could facilitate concentration-independent nitric oxide response.
Another example of a target other than pH or temperature was demonstrated by Sherry
and co-workers who achieved a concentration-independent response to singlet oxygen using 1.23
(Figure 1.19).70 The incorporation of a 9-anthryl group facilitated an irreversible reaction with
singlet oxygen to form 1.24, and the ~3 ppm (Figure 1.20) chemical shift difference between the
amide protons before and after response enabled ratiometric CEST imaging. The use of CEST
imaging allowed for the formation of singlet oxygen to be observed from the disproportionation
of H2O2 catalyzed by MoO42– (Figure 20b) because the CEST ratio is also a ratio of product over
reactant. In vitro phantom images of singlet oxygen response enabled quantification of singlet
oxygen after presaturation at 55 and 48 ppm downfield from bulk water.

Figure 1.19. Structures of 1.23 and the product of its reaction with singlet oxygen (1.24).70
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Figure 1.20. (A) Ms/M0 as a function of saturation offset for increasing concentrations of singlet
oxygen at 9.4 T and 298 K. Inset: Enlarged view. (B) CEST ratio as a function of concentration
of singlet oxygen. Adapted from Ref. 70 with permission from The Royal Society of Chemistry.
A new ratiometric CEST method using different radiofrequency powers was recently
reported by Aime and co-workers.86 In this technique, a ratio, which has been named the ratio of
radiofrequency power mismatch, is calculated by the quotient of saturation transfer at two
different radiofrequency powers as seen in Eq 1.7, where ST is the measured saturation transfer
and RF1 and RF2 are the first and second radiofrequency powers used to measure saturation
transfer. Importantly, radiofrequency power mismatch is dependent on pH (pH-dependence
indicates temperature dependence as well, but this was not demonstrated in the report) and
radiofrequency power, but it is independent of the concentration of contrast agent. Using the
radiofrequency power mismatch approach, Aime and co-workers demonstrated both in vitro and
in vivo pH detection using radiofrequency powers of 1.5, 3, and 6 µT.86
Eq 1.7

𝑟𝑎𝑑𝑖𝑜𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑝𝑜𝑤𝑒𝑟 𝑚𝑖𝑠𝑚𝑎𝑡𝑐ℎ =

[(1−ST)/ST]𝑅𝐹1
[(1−ST)/ST]𝑅𝐹2
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The use of ratiometric imaging has worked well for contrast agents that produce two
CEST signals with unique pH dependencies. The ratiometric approach, however, is not limited to
CEST imaging applications. In the next section, examples of ratiometric imaging using
relaxation rates are highlighted.
1.2 Ratiometric Relaxation Rates
The absence of GdIII-containing contrast agents in the previous section is primarily due to
the relatively slow electronic relaxation time (T1e) of GdIII compared to other LnIII metal ions.22–
24

The result of a relatively slow T1e is that GdIII will relax protons efficiently. In fact, GdIII

relaxes nearby protons so quickly that complexes containing GdIII and exchangeable protons
(amine, amide, hydroxyl, and bound water) will not exhibit CEST effect.87 On the other hand,
GdIII is an efficient positive contrast agent because it can drastically decrease the T1 of nearby
protons. However, as discussed in the introduction, merely changing the relaxivity of a Gd IIIcontaining complex will impose a concentration-dependence on the response of the agent, which
limits its practicality in vivo. Therefore, neither ratiometric CEST nor changes in relaxivity are
sufficient for the design of concentration-independent responsive contrast agents containing
GdIII. Instead, changes in both longitudinal and transverse relaxation rates can be used for
ratiometric imaging.
Aime and co-workers proposed using the ratio between the transverse and longitudinal
paramagnetic contribution to relaxation rates (R2p/R1p) as a concentration-independent handle for
pH detection.50 The transverse and longitudinal relaxation rates are the inverse of the transverse
and longitudinal relaxation times T2 and T1, respectively. The rationale for this approach can be
explained using Eq 1.8–1.10 (commonly used to describe bound water proton contributions to
relaxation rates), where PM is the mole fraction of water protons bound to GdIII ([Gd]/55.6), τM is
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the residence lifetime of the bound water protons, and T2M and T1M are the transverse and
longitudinal relaxation times of the bound water protons. Individually, R1p and R2p are
concentration-dependent because of PM (Eq 1.8 and Eq 1.9), whereas PM is cancelled in the ratio
(equation 10). Neither T1M nor T2M are concentration-dependent, but they are both dependent on
the rotational correlation time (τR).22–24 Therefore, changes in τR are expected to cause changes in
both T1M and T2M. Likewise, changes in T1M and T2M are expected to cause changes in the R2p/R1p
ratio (Eq 1.10), which remains concentration-independent. Accordingly, changes in τR are
predicted to cause changes in the ratio of relaxation rates. The connection between τR and
relaxation rates was used for pH response using 1.25 (Figure 1.21) by a reversible,
conformational transition between α-helical and random coil conformers.50 The change in
conformation caused a change in τR, which caused a change in the ratio of relaxation rates. Using
21, a ratiometric response to pH was demonstrated that was independent of the concentration of
contrast agent (Figure 1.22).
Eq 1.8

𝑅1p ≃

Eq 1.9

𝑅2p ≃

Eq 1.10

𝑅2p
𝑅1p

≃

𝑃M
𝑇1M + 𝜏M
𝑃M
𝑇2M + 𝜏M
𝑇1M + 𝜏M
𝑇2M + 𝜏M

Figure 1.21. Structure of 1.25 used for concentration-independent pH measurements using
ratiometric relaxation rates.50
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Figure 1.22. Left: Relaxation rate ratio as a function of GdIII concentration at pH 7 (■), 8.5 (),
10 (▲), and 12 (♦). Right: Relaxation rate ratio as a function of pH. All measurements were
recorded at 14 T and 25 °C. Adapted with permission from S. Aime, F. Fedeli, A. Sanino and E.
Terreno, J. Am. Chem. Soc., 2006, 128, 11326. Copyright 2006 American Chemical Society.
In a recent study, Digilio, Aime, and co-workers applied the R2p/R1p approach to detect
matrix metalloproteinase-2 activity.88 Instead of relying on reversible changes to molecular
conformation, an irreversible reaction was used to change R2p/R1p by an enzyme-catalyzed
cleavage of a peptide. Before enzyme cleavage, 1.26 (Figure 1.23) remained embedded within a
liposome membrane, which forced the complex to have a relatively long τR because of the slow
molecular reorientation of liposomes compared to small molecules.89 Upon reacting with matrix
metalloproteinase-2, 1.27 was cleaved from the liposome membrane and, consequently,
experienced a decrease in τR.88 As discussed previously, changes in τR induce measurable
changes in R2p/R1p that are independent of contrast agent concentration. By measuring R2p/R1p of
1.26 embedded in liposomes exposed to matrix metalloproteinase-2, the activity was measured
and the response was found to be independent of the concentration of contrast agent (Figure
1.24).
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Figure 1.23. Structure of a contrast agent that is responsive to the activity of matrix
metalloproteinase-2 before (1.26) and after (1.27) peptide cleavage by the enzyme.88

Figure 1.24. R2p/R1p as a function of contrast agent concentration (CT) demonstrating
concentration-independence and that R2p/R1p responds to decreasing mole fraction of 1.26 (χGdL).
Figure adapted with permission from A R2p/R1p Ratiometric Procedure to Assess Matrix
Metalloproteinase-2 Activity by Magnetic Resonance Imaging/V. Catanzaro, C. V. Gringeri, V.
Menchise, S. Padovan, C. Boffa, W. Dastrù, L. Chaabane, G. Digilio and S. Aime/Angew. Chem.
Int. Ed., 52/14. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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In the previous examples of ratiometric relaxation rates, the authors observed that the
R2p/R1p ratio was also dependent on external magnetic field strength. In a different report, a
ratiometric approach to pH measurement was developed by measuring R1p at two different
magnetic field strengths.51 A magnetic field strength dependence can be seen in Eq 1.11 and Eq
1.12, where R1p is determined through r1p, which is field strength-dependent, and GdIII
concentration at the respective magnetic field strengths (1 and 0.2 T). The ratio of R1p at different
magnetic field strengths (Eq 1.13) cancels the requirement for GdIII concentration. Using the
amphiphilic complex 1.28 (Figure 1.25) in liposomes, Aime and co-workers were able to
measure solution pH within 3.5% error compared to a pH electrode (Figure 1.26).51 The
mechanism of pH response was investigated using NMR dispersion profiles. It was proposed that
acidic pH values facilitated the protonation of the sulfonamide nitrogen, which would prevent
coordination to GdIII to leave vacant sites for water coordination. Furthermore, when the
complex remains protonated and neutral, it can embed itself within the hydrophobic region of the
liposome membrane causing an increase in membrane permeability. Upon changing the pH to
alkaline values, the nitrogen of the sulfonamide arm could be deprotonated to form an anionic
complex (1.29). The anionic complex had less affinity for the hydrophobic region of the
membrane and fewer vacant sites for water coordination. These reversible structural changes
were used to explain differences in R1p at different pH values. It should be noted that changing
the external magnetic field strength has been previously used to highlight areas of an albuminbound contrast agent in vivo.90
Eq 1.11

𝑅1p(1 T) = 𝑟1p(1 T) × [Gd]

Eq 1.12

𝑅1p(0.2 T) = 𝑟1p(0.2 T) × [Gd]
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Eq 1.13

𝑅1p(1 T)
𝑅1p(0.2 T)

𝑟1p(1 T)

=𝑟

1p(0.2 T)

Figure 1.25. Structure of 1.28 and 1.29 used for ratiometric relaxation rate measurements at
different magnetic field strengths for concentration-independent measurements of pH.51,53

Figure 1.26. pH measured using liposome-encapsulated 1.28 and the ratiometric R1P approach vs
pH measured by an electrode. Adapted with permission from E. Gianolio, S. Porto, R.
Napolitano, S. Baroni, G. B. Giovenzana and S. Aime, Inorg. Chem., 2012, 51, 7210. Copyright
2012 American Chemical Society.
In a cautionary tale, Pierre and co-workers attempted to use ratiometric relaxivity (r1/r2)
of magnetic iron oxide nanoparticles to circumvent the need for contrast agent concentration.91
Briefly, magnetic iron oxide nanoparticles can be coated with organic substrates capable of
inducing nanoparticle aggregation upon exposure to the desired target. The change in the
relaxivity ratio before and after aggregation can be used to determine response, and the ratio of
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r1/r2 can be used to circumvent the need to know contrast agent concentration. While this
technique had been previously reported using magnetic iron oxide nanoparticles for the detection
of oligonucleotides,92 antibodies,92 enzymes,92,93 proteins,94 and viruses,95 Pierre and co-workers
observed that aggregation does not result in a constant increase in transverse relaxivity, but
rather produces a bell-shaped curve as a function of aggregate size. Therefore, they argued that
using r1/r2 to measure the concentration of analyte without knowledge of contrast agent
concentration is inaccurate for magnetic iron oxide nanoparticles.
While ratiometric techniques can be powerful when coupled with the appropriate contrast
agent, there exists a separate option which does not require ratiometric measurements. To avoid
ratiometric analysis, one can detect the contrast agent using different imaging modalities instead.
1.3 Multimodality Imaging
An alternative to using ratiometric methods for concentration-independent responsive
contrast agents is to use two detection modes (dual-mode) for imaging. In dual-mode imaging,
the contrast agent of interest can be detected using two or more imaging modes such as 1H- (T1weighted, T2-weighted, or CEST),
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P-, and

19

F-MRI, positron emission tomography (PET), or

single-photon emission computed tomography (SPECT). An attractive feature of dual-mode
imaging is that one mode can be used to detect a response while the other mode can act to
monitor the location of the contrast agent and, in some cases, its concentration for quantification
of the target molecule. Measuring the concentration of a contrast agent differentiates dual-mode
imaging

from

ratiometric

strategies

to

overcome

concentration-dependence

because

determination of concentration is not possible or necessary using the ratiometric CEST or
relaxation rate techniques described in the previous sections.
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Aime and co-workers used a combination of

19

F- and 1H-MRI for measuring pH by

incorporating 1.30 and 1.31 (Figure 1.27) into poly-β-cyclodextrin (polymeric form of βcyclodextrin consisting of 8–10 units).55 It had been previously demonstrated that adamantane
derivatives have a strong binding affinity for β-cyclodextrin,96 and it was assumed that both 1.30
and 1.31 were anchored into the polymer through the adamantane moiety. By controlling the
molar ratio of 1.30/1.31/poly-β-cyclodextrin (1:5:20), the
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F-MRI signal was measured and

quantified using an external standard (25 mM of NaPF6). The external standard was used to
quantify the amount of 1.31, which was used to infer the concentration of 1.30 because the molar
ratios were known. The second mode of imaging, 1H-MRI, was used to measure the T1 of the
solution, which was affected by the protonation state of 1.30. Accordingly, the T1 of the solution
and the concentration of 1.30 were known, and r1 could be determined to detect the response. It
should be noted that this method does not circumvent the need for knowledge of concentration,
but it does provide a way to quantify the concentration of contrast agents to detect responses. A
benefit of using
signal of

19

19

F as a handle for contrast agent quantification is the minimal background

F in vivo; however, relatively slow

19

F relaxation times limit the sensitivity of

detection necessitating millimolar levels of contrast agent in tissues.79 A different isotope,
can also be used for dual-mode imaging, but in a much different manner.

18

F,

31

Figure 1.27. Structure of adamantane-functionalized contrast agents used for 1H- (1.30) and 19FMRI (1.31, stereochemistry of hydroxyl group not specified).55
Caravan and co-workers used 1H-MRI and PET for quantitative pH imaging.52 Their
method, in a similar fashion to that used in the previous example, relied on external standards to
quantify the concentration of agent present. Instead of using
determination, they used the positron-emitting isotope
positron-emitting isotope (for example,
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C,

13

N,

15

O,

18

18

19

F as the handle for concentration

F. Briefly, PET operates by using a

F,

64

Cu,

66

Ga, or

82

Rb), which can be

incorporated into a compound of interest to produce a radiotracer. The radioactive isotope within
the radiotracer decays through positron emission, and the emitted positron travels until its energy
is low enough to permit interaction with an electron resulting in an annihilation event. The
annihilation between a positron and electron produces two gamma rays that travel in opposite
(~180°) directions. A gamma detector can measure the time difference between two coincident
gamma rays to calculate the location of the radiotracer. The gamma ray background of humans is
small relative to the proton background, which makes PET extremely sensitive. Additionally,
gamma activity can be used to quantify the amount of radiotracer present. Using 1.32 (Figure
1.28),52 Caravan and co-workers quantified the amount of contrast agent present using PET
imaging with external standards. The second mode of imaging, T1-weighted 1H-MRI, was used
to determine the T1 of the solution. Similar to the previous example, knowing both the T1 of the
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solution and the contrast agent concentration allows for r1 to be determined, and a quantitative
response can be measured (Figure 1.29). An important feature of this dual-mode technique is
that the MRI and PET imaging were performed simultaneously (whereas most other dual-mode
strategies use sequential imaging), which means that diffusion of the contrast agent would not
pose a problem in vivo.

Figure 1.28. Structure of 1.32 used for dual-mode PET and 1H-MRI for quantitative pH
measurements.52 Phosphonates are drawn singly protonated because of the expected pKa values
of the first (pKa ≈ 2–3) and second (pKa ≈ 7–8) phosphonate oxygen atoms.

Figure 1.29. pH determined with the MR/PET technique vs pH determined using a glass
electrode. The solid line represents a linear fit of the data and the dashed line represents a
hypothetical 1:1 correspondence between the x- and y-axes. Figure adapted with permission
from Bimodal MR–PET Agent for Quantitative pH Imaging/L. Frullano, C. Catana, T. Benner,
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A. D. Sherry and P. Caravan/Angew. Chem., 122/13. Copyright © 2010 WILEY-VCH Verlag
GmbH & Co. KGaA, Weinheim.
In a similar fashion to the example above, Aime and co-workers used 1H-MRI and
SPECT to detect changes in pH using 1.28 and its isostructural 166HoIII-containing analogue as a
radiotracer.53 SPECT operates in a similar fashion to PET, but the radioisotope emits gamma
rays directly instead of through an indirect annihilation event. The direct emission of gamma
rays causes SPECT to have lower sensitivity relative to PET because the radiotracer cannot be
detected through coincident gamma rays. A decrease in sensitivity of SPECT means that
temporal resolution must suffer to achieve adequate contrast, and longer acquisition periods
allow for contrast agents to diffuse to a greater extent. In this example, the radiotracer acted as a
calibration standard to infer the concentration of 1.28. Knowing the concentration of 1.28
allowed for a pH response to be measured.53 A difference between this MRI-SPECT dual-mode
strategy and the previously discussed MRI-PET strategy is that the MRI-SPECT strategy
requires sequential imaging, which can allow contrast agent diffusion to occur resulting in
increased chances for error. Most of the examples highlighted throughout this chapter focus on
both responding to and quantification of stimuli. It can be argued, however, that quantification of
stimuli is not always necessary to obtain important information in a concentration-independent
way. To detect a response without quantification, a threshold response must be used.
1.3.1 Threshold Response
In the first three examples within the dual-mode section, external standards were used to
quantify contrast agents that responded to pH. In this manner, the concentration could be inferred
indirectly. Alternatively, dual-mode can be used without any knowledge of the concentration of
contrast agent. The use of EuII-containing complexes, such as 1.33 (Figure 1.30), is potentially
advantageous because r1 increases at ultra-high magnetic field strengths (≥7 T),97–99 whereas the
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r1 of GdIII-containing complexes decrease.100 Furthermore, higher magnetic field strengths can
lead to greater spatial and temporal resolutions that are desirable for diagnostic scans. However,
a limitation with EuII is its propensity to oxidize to EuIII. The oxidation potential of EuII can be
modulated through structural modifications to the ligand, and some of the reported modifications
result in the most positive oxidation potentials (more resistant to oxidation) ever reported in
aqueous solution.101–103 While the threshold strategy does not quantify the amount of oxidant
present, it can report if an oxidation threshold has been crossed. The oxidation of EuII-containing
complexes will be discussed within the context of responsive contrast agents for MRI in the
remaining chapters of this thesis.

Figure 1.30. Structure of 1.33 used for liposome encapsulation to demonstrate a response to
oxidation using CEST and T1-weighted 1H-MRI.73
The dual-mode examples so far have been used for in vitro imaging, but the next section
will highlight examples that have used internal standards to indirectly measure the concentration
of contrast agent, but for in vivo imaging.
1.4 Dual-Injection Imaging
An alternative to using external standards or ratiometric techniques is to use an internal
standard to indirectly monitor the biodistribution of a responsive contrast agent. In doing so, one
must make the assumption of (or demonstrate) sufficiently similar pharmacokinetics of two
separate complexes. Raghunand and co-workers monitored the time-dependent distribution of
1.34 and 1.35 (Figure 1.31) after sequential tail-vein injections.56 Previously, Sherry and co-
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workers had demonstrated the pH-dependency of the r1 of 1.34,37 where the hydrogen-bonding
network of the pendant arms was influenced by changes in protonation state. Interestingly, 1.35
is pH-insensitive despite some structural similarities with 1.34. Ragnhunand and co-workers
demonstrated that 1.34 and 1.35 had comparable biodistribution within the mouse model and that
the concentration of 1.34 could be inferred by tracking 1.35 through T1-weighted images. Using
1.34 and 1.35, in vivo pH maps were generated to demonstrate kidney alkalinization (Figure
1.32) induced by treatment with the carbonic anhydrase inhibitor acetazolamide.

Figure 1.31. Structure of 1.34, 1.35, 1.36 used to generate in vivo pH maps using a dualinjection strategy.56,104,105

Figure 1.32. Calculated pH maps of mouse kidneys generated using the dual-injection strategy
of a mouse without (left) and with (right) acetazolamide treatment demonstrating alkalinization
of kidneys. A pH scale bar is on the far right. Figure adapted with permission from Renal and
Systemic pH Imaging by Contrast-Enhanced MRI/N. Raghunand, C. Howison, A. D. Sherry, S.
Zhang and R. J. Gillies/Magn. Reson. Med., 49/2. Copyright © 2003 Wiley-Liss, Inc.
In a subsequent report, Gillies and co-workers applied the dual-injection strategy using
1.34 and 1.35 (Figure 1.31) to generate pH maps of tumors,104 which they argued is significantly
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more difficult than imaging kidneys due to the heterogeneous distribution of blood vessels,
slower diffusion of agent, and higher protein concentrations of the extracellular fluid. Due to
these challenges, the authors accounted for the potential of residual 1.35 to be present in the
tumor microenvironment at the time 1.34 was injected. To correct for residual 1.35, they
modeled how quickly 1.35 washed out of tumors using a bi-exponential equation on a pixel-bypixel basis and the extrapolated residual signal from 1.35 was used as a background subtraction
for 1.34 pharmacokinetics. Expectedly, the average pharmacokinetics of 1.34 and 1.35 were
similar, but the authors observed that local differences (pixel-by-pixel) reduced the apparent
pharmacokinetic correlation of the two contrast agents. To correct for these differences, pH maps
were calculated using the maximal enhancement per pixel. Using the aforementioned techniques
to account for tumor heterogeneity, Gillies and co-workers were able to calculate pH maps of
mouse gliomas.104
In the previous two examples of dual-injection imaging, sequential injections were used.
However, the dual-injection strategy does not require sequential injections. A relatively severe
limitation of sequential injections is temporal resolution, where images were collected for 1 h
after the injection of each contrast agent for the previous two examples. To improve the temporal
resolution, two contrast agents can be injected simultaneously.
Recently, a single cocktail approach was developed by Martinez and co-workers using
1.34 and 1.36 for pH mapping of tumors.105 In the previous approaches, sequential injections
were required because 1.34 and 1.35 both produce T1 enhancement such that they would be
indistinguishable if injected simultaneously. By using 1.36 as the pH-insensitive handle to track
biodistribution, however, the presence of 1.36 could be detected by its influence on the rate of
phase decoherence of the nuclear dipole moments of neighbouring protons. Importantly, 1.36
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had a negligible influence on T1. This approach is a dual-injection, dual-mode strategy because
of the use of two contrast agents and detection with both T1- and T2-weighted imaging. By (1)
using a contrast agent cocktail with a controlled molar ratio of 1.34/1.36 (1:2) and (2) assuming
near identical pharmacokinetics of 1.34 and 1.36 based on previous reports comparing 1.34 and
1.35,104 this strategy was used to produce pH maps of tumors with improved temporal resolution
relative to sequential injection strategies (20–90 min vs 120 min).
Throughout this chapter, pH has been detected in a variety of ways. As previously
discussed, pH is an intuitive target for detection because 1H-MRI directly detects protons and
changes in proton-exchange can be used to calculate pH. In the next section, a rather unique
approach to pH detection is discussed that involves perturbations in the ligand field of lanthanide
ions.
1.5 Ligand Field-Induced Chemical Shift
LnIII ions were once thought to be static spheres of positive charge with unchanging
luminescence and magnetic properties due to the limited radial distribution of 4f-orbitals. It has
been demonstrated, however, that some LnIII ions have spectroscopic and magnetic properties
that are relatively sensitive to changes in the coordination environment (ligand field) of the metal
ion.54,106 Of importance to this chapter, ligand field changes can influence the effective magnetic
moment of LnIII ions, which is likely due to changes in the geometry of ligand distribution about
the metal ion. Recently, Parker and co-workers demonstrated a pH response using ligand fieldinduced chemical shift.54 Upon moving to acidic pH values, the concentration of 1.37 decreased
as the protonated form 1.38 increased (Figure 1.33). Specifically, the 1H resonance frequency (–
58 ppm) of a nearby (~6.6 Å) tert-butyl group was used to monitor the change in protonation
state. As the pH was lowered, the signal intensity at –58 ppm decreased. The response was
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detected ratiometrically by using an analogous tert-butyl group on 1.39 at –18 ppm. Importantly,
1.39 did not possess the same pH-dependence as 1.37. Accordingly, the ratio of tert-butyl signal
intensities (–58 ppm/–18 ppm) in a solution containing 1.37/1.39 (1:1) reported the pH of the
solution over a range of 4 to 7 (Figure 1.34).
It is important to emphasize that this example is not based on a CEST mechanism
because an exchangeable proton is not being selectively saturated and, therefore, saturation
transfer is not being used. Instead, the ligand field of a Ln III-containing complex is perturbed
through a change in protonation state, and the perturbed ligand field influences the effective
magnetic moment. The altered magnetic moment then influences the chemical shift values of
nearby protons. While Parker and co-workers did not demonstrate concentration-independence in
this example, the response is inherently concentration-independent because of its ratiometric
nature (assuming similar kinetic stability and that the concentration ratio of the two contrast
agents is known and does not change over the course of imaging). A possible avenue for future
developments that involve ligand field-induced chemical shifts would be to covalently attach two
compounds, such as 1.37 and 1.39 (Figure 1.33), to ensure that differences in pharmacokinetics
are not a concern, but the covalent linkage would need to be long enough to prevent changes in
the ligand field of one metal center to influence proton resonances on the other. A separate
avenue could be to revisit some of the contrast agents that respond to changes in water
coordination number,16 because ligand field-induced chemical shift might offer a platform for
more ratiometric probes using previously reported chemical responses.

39

Figure 1.33. Structure of 1.37 and its protonated form 1.38 that alter the chemical shift of tertbutyl protons through changes in ligand field. The ratiometric pH response was measured using
1.39 as a secondary compound with a different pH dependence.54

Figure 1.34. Ratio of tert-butyl proton chemical shift intensities of 1.37 and 1.39 as a function of
pH. Reproduced from Ref. 54 with permission from The Royal Society of Chemistry.
The challenge of overcoming concentration-dependence in responsive contrast agents for
MRI has been approached from many different angles. Ratiometric CEST, ratiometric relaxation
rates, dual-mode, dual-injection, and ligand field-induced chemical shift strategies have been
employed to push the field towards in vivo applicability and, in some cases, have already made
the leap to in vivo imaging. While there have been substantial developments toward the goal of
overcoming concentration-dependence, there is still work to be done. For instance, much of the
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effort in the area has focused on concentration-independent pH imaging, but the examples of
other targets are relatively few. One of the largest limitations of contrast agents that provide
contrast through proton exchange is relatively low sensitivity (millimolar concentrations in
tissue) because they must provide contrast that is distinguishable from the relatively large proton
background in vivo. Coupling MRI with the extremely sensitive PET imaging modality still
imparts a sensitivity limitation because PET is used to quantify the agent whose response is
detected through 1H imaging techniques. The ligand field-induced chemical shift approach offers
an interesting platform for large sensitivity gains because contrast agents can be designed to
contain large numbers of chemically equivalent protons to boost the sensitivity. Another
limitation with strategies that use a combination of detection methods (multiple CEST
frequencies, contrast agents, or pulse sequences) to circumvent concentration-dependence is that
the error associated with each detection method is propagated to the final measurement.
Additionally, some strategies forgo practical temporal resolutions to obtain exquisite
quantification of analyte. Although the results are impressive, the clinical usefulness might not
be realized until acquisition times are substantially reduced.
Regardless of the current set of limitations within the field and within the individual
strategies, momentum is building toward a new class of contrast agents capable of reporting real
time responses in vivo. With the advent of the strategies reported in this chapter and,
undoubtedly, new strategies to come, one may envision a sharp increase in the number of
contrast agents for MRI undergoing clinical trials. Arguably, one of the biggest barriers
preventing the clinical application of responsive agents (other than target-specific delivery)107,108
is concentration-dependence. Accordingly, all progress toward overcoming concentration-
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dependence in responsive contrast agents for MRI has the potential to significantly and
positively impact diagnostic molecular imaging.
Research Design
This thesis is centered on the ability of the EuII ion to undergo a one-electron oxidation
resulting the in the loss of detectable positive contrast enhancement. If the oxidation of EuII to
EuIII occurs quantitatively, all detectable positive contrast enhancement will be lost. The
quantitative oxidation of EuII can be used to overcome the concentration-dependent response to
oxidation because, assuming complete oxidation, the concentration of complex is not required to
infer a response. If the oxidation of EuII is not quantitative, positive contrast enhancement might
be detected and the response would be dependent upon concentration. Accordingly, the ability to
detect oxidation in a concentration-independent manner relies on the complete oxidation of EuII
to EuIII resulting in the complete loss of positive contrast enhancement. Furthermore, to
differentiate oxidation of EuII from clearance of EuII, the EuIII-containing complex after
oxidation would need to be detected using a different imaging modality.
The use of a divalent lanthanide represents a new approach to contrast-enhanced MRI.
While EuII is the most stable divalent lanthanide with respect to oxidation, it is still prone to
oxidation by oxygen. Accordingly, the use of EuII-containing complexes in responsive MRI
necessitates fundamental studies regarding viable routes of administration, biodistribution,
persistence in tissues with varying levels of oxygen, detection after oxidation to Eu III, and kinetic
stability. To uncover this fundamental information, this thesis describes the synthesis,
characterization, and in vitro and in vivo application of EuII-containing complexes within the
context of responsive contrast agents for MRI.
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In Chapter 2, the evaluation of EuII-based positive contrast enhancement after
intravenous, intraperitoneal, and subcutaneous injections is described. T1-weighted MRI as a
function of time reveal a correlation between reported tissue oxygenation and the persistence of
EuII-based positive contrast enhancement. Biodistribution trends after intravenous and
intraperitoneal injections are also described. This study provides fundamental information
regarding the in vivo behavior of a EuII-containing complex that is likely applicable to other EuIIcontaining complexes.
In Chapter 3, the synthesis and solid- and solution-phase characterization of a 4fluorobenzo-functionalized EuII-containing complex is described. The ability of the complex to
differentiate necrotic (oxygen deficient) from non-necrotic tissue after intratumoral injection is
described and supported by histological staining. Accordingly, Chapters 2 and 3 describe
fundamental information regarding route of administration of EuII-containing complexes, the
transitory nature of EuII-based positive contrast enhancement, and the ability of EuII to
differentiate necrotic tissue within a tumor model. While the persistence of EuII-based positive
contrast enhancement can be informative, the loss of EuII-based positive contrast enhancement is
not meaningful if oxidation and clearance events are indiscernible. The need to discern oxidation
from clearance motivates the study of EuII-containing complexes that are detectable with MRI
after oxidation of EuII to EuIII. Accordingly, the focus of this thesis shifts to the detection of
complexes after oxidation using CEST in the remaining chapters.
In Chapter 4, the encapsulation of 1.33 in liposomes with air-free purification and
characterization is described. Additionally, the detection of the liposomes by T1-weighted and
CEST imaging are described and demonstrate the ability to visualize the contrast agent before
and after oxidation of EuII. This proof-of-concept study demonstrates the first EuII-based
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responsive contrast agent and offers an approach to discerning oxidation from clearance as
discussed in Chapters 2 and 3.
In Chapter 5, the synthesis and characterization of a responsive Eu II-containing
tetraglycinate complex is described. This particular study differs from those previously discussed
in that a commercially available EuIII-containing complex, 1.9, is used as the starting material.
The use of 1.9 was motivated by its CEST signal being ~50× further from the bulk water proton
resonance than the CEST signal from liposomes. Furthermore, favorable electron-transfer
reversibility and kinetic stability are described. The commercial availability, ease of preparation,
and robust electron-transfer properties provide an excellent starting point for a new class of
redox sensors based on the EuII/III redox couple.
Chapter 6 combines the major findings of Chapters 2–5 into a cohesive summary.
Additionally, this chapter discusses important directions in which the results of this research can
be built upon.
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CHAPTER 2: EVALUATION OF EUROPIUM(II)-BASED POSITIVE CONTRAST
ENHANCEMENT AFTER INTRAVENOUS, INTRAPERITONEAL, AND
SUBCUTANEOUS INJECTIONS
Parts of this chapter were adapted with permission from Ekanger, L. A.; Polin, L. A.; Shen, Y.;
Haacke, E. M.; Allen, M. J. Contrast Media Mol. Imaging [Online early access].
10.1002/cmmi.1692. Published Online: March 30, 2016. Copyright © 2016 WILEY-VCH
Verlag GmbH & Co. KGaA, Weinheim.
2.1 Introduction
Redox balance is critical to the homeostasis of living tissues, and redox stress is
associated with some cancers109–112 and ailments such as cardiovascular,113,114 Alzheimer’s,115–118
liver,119,120 and chronic kidney disease.121 The ability to noninvasively detect changes in redox
environments in real time would be invaluable to diagnosing diseases and monitoring responses
to therapies. MRI offers a noninvasive platform to image opaque objects, but often requires
responsive contrast agents to relay chemical information regarding the local redox environment.
The GdIII ion has dominated the clinical landscape and preclinical research in MRI because it
provides excellent T1-shortening (positive) contrast enhancement,24,122,123 but GdIII is restricted to
the 3+ oxidation state under physiological conditions preventing metal-based redox responses.124
The EuII ion is isoelectronic with GdIII (4f7), and both ions provide positive contrast enhancement
in MRI.73,97–99,102,125–129 Additionally, EuII can be oxidized by one electron to produce the EuIII
ion that does not enhance positive contrast.73 The complete loss of positive contrast enhancement
upon the oxidation of EuII offers a unique platform for concentration-independent redox
sensing.124 However, there is still much to be learned about the nature of EuII-based contrast
agents in vivo, including establishing routes of administration and biodistribution trends. In this
chapter, the evaluation of in vivo EuII-based contrast enhancement in MRI is presented after
intravenous, intraperitoneal, and subcutaneous injections using
Biodistribution trends are also presented.

1.33 (Figure 1.30).

45

The ability of 1.33 to impart oxidative stabilization of the 2+ oxidation state of europium
has been studied,103,130 and recent reports have characterized the aqueous magnetic and
electrochemical properties of 1.33 and other EuII-containing complexes.73,97–102,125–129,131–133
Despite increased oxidative stability, the EuII ion of 1.33 is prone to rapid oxidation by oxygen in
solution.125 Oxidation of EuII in elevated oxygen partial pressures coincides with the loss of
positive contrast enhancement,73 and this change in contrast enhancement was expected to be
observable in vivo. The 2+ oxidation state of europium is expected to persist for hours within
relatively oxygen-deficient tissue (pO2 < 10 mmHg); therefore, regions containing relatively
higher levels of dissolved oxygen such as the subcutaneous space, fluids of the peritoneal cavity,
and blood (Figure 2.1) were chosen to evaluate the effect of differing oxygen partial pressures.

Figure 2.1. pO2 ranges in necrotic and non-necrotic tumor (converted from percent hemoglobin
saturation using a hemoglobin saturation curve),134,135 subcutaneous space,136 venous blood,136
the peritoneal cavity,137 and arterial blood.136
2.2 Experimental Procedures
2.2.1 General Procedures
Commercially available chemicals were of reagent-grade purity or better and were used
without further purification unless otherwise noted. Water was purified using a PURELAB Ultra
Mk2 water purification system (ELGA) and degassed prior to use.
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2.2.2 Preparation of Contrast Agent Solutions
Contrast agent solutions for intravenous, intraperitoneal, and subcutaneous injections
were prepared by adding aqueous EuCl2 and aqueous 4,7,13,16,21,24-hexaoxa-1,10diazabicyclo[8.8.8]hexacosane in a 1:1 ratio to a 4 mL glass vial equipped with a magnetic stir
bar under an atmosphere of N2. The resulting clear, colorless solution was stirred for 1 h before
addition of the 10× phosphate buffered saline (PBS, Fisher BioReagents) and water to achieve a
final solution of 1.33 (4 mM) in PBS (11.9 mM phosphates, 137 mM NaCl, and 2.7 mM KCl).
The clear, colorless solution was stirred for 30 min then filtered through a 0.2 µm hydrophilic
filter. The concentration of europium in the clear, colorless filtrate was determined by ICP–MS
and was used directly for imaging studies.
2.2.3 ICP–MS
ICP–MS measurements were acquired on an Agilent Technologies 7700 series
spectrometer in the Lumigen Instrument Center at Wayne State University. All dilutions were
performed with 2% HNO3 that was also used for blank samples during calibration. The
calibration curve was created using the
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Eu isotope ion count for a 10–100 ppb concentration

range (diluted from Fluka ICP standard solution, Eu2O3 in aqueous 2% HNO3, 1000 mg Eu/L),
and samples (with the exception of tissue digestion) were diluted to fall within this range.
2.2.4 Magnetic Resonance Imaging
Studies in animals were carried out with the assistance of the Animal Model and
Therapeutics Evaluation Core of the Barbara Ann Karmanos Cancer Institute after approval from
the Wayne State University Institutional Animal Care and Use Committee. MRI scans were
performed in the Elliman Clinical Research Building at Wayne State University with a 7 T
Bruker Clinscan small animal MRI scanner equipped with a 30 cm bore. T1-weighted images
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(3D FLASH) were acquired with a body coil while using a warm water circulator set to 37 °C.
The whole body coronal plane images were acquired using an echo time of 1.5 ms, repetition
time of 11 ms, flip angle of 40 degrees, 44 image slices at 0.5 mm thickness, and a 31 mm × 90
mm field of view, and an in plane resolution of 0.352 mm × 0.352 mm.
For intravenous injections, mice were catheterized before being anesthetized with
isoflurane. A micro-volume extension set was used to inject the solution of 1.33 into the tail vein
without removing the mouse from the magnet. A correction volume (0.08 mL) was added to the
calculated dose volumes for intravenous injections to account for the volume of the phosphatebuffered saline within the catheter. For intraperitoneal and subcutaneous injections, mice were
first anesthetized with isoflurane, imaged prior to injection, and then the cradle with the mouse
was removed from the magnet to perform the injection while still anesthetized. After injections,
mice were imaged immediately to acquire the first time points post-injection. Intravenous
injections were triplicated, intraperitoneal injections were duplicated, and the subcutaneous
injection was performed once.
2.2.5 Biodistribution Studies
For biodistribution studies, mice were not catheterized or anesthetized. Mice were
injected with the same europium dose used for imaging (3 mg/kg) before being sacrificed 1 h
post-injection at which point the blood, liver, kidneys, spleen, heart, bone (femur), muscle
(thigh), brain, upper and lower GI tract, stomach, and lungs were harvested. The samples were
weighed, freeze dried for 72 h, and digested in 25 mL volumetric flasks using 6 mL of 3 M nitric
acid at 75 °C with constant stirring for 16 h. The entirety of each sample was used for digestion
with the exception of the liver, which was homogenized with mortar and pestle prior to addition
to a volumetric flask and a fraction (~130 mg) of the homogenate was added to a volumetric
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flask. After 16 h, the digests were allowed to cool to ambient temperature before the addition of
water to achieve a total volume of 25 mL. The digests were transferred to conical tubes (50 mL)
and insoluble oils were removed by centrifugation. The clear, yellow supernatants were
immediately transferred to conical tubes (15 mL) for analysis of europium concentration with
ICP–MS.
2.3 Results and Discussion
To evaluate the nature of positive contrast enhancement of 1.33 as a function of injection
type, T1-weighted images of mice were acquired after administering 1.33 (0.1 mL, 4 mM,
europium dose of 3 mg/kg) through intravenous, intraperitoneal, and subcutaneous injections
(Figure 2.2). Mice were imaged prior to injection and at 3 and 8 min to compare responses with
the three injection types. Based on these images, the intravenous injection resulted in no positive
contrast enhancement; the intraperitoneal injection led to positive contrast enhancement in the
peritoneal cavity that disappeared by 8 min; and the subcutaneous injection produced positive
contrast enhancement both 3 and 8 min post-injection. The absence of positive contrast
enhancement after the intravenous injection suggests that 1.33 was oxidized within the first 3
min in the blood. Although this observation is inconsistent with the low oxygen content of
venous blood (relative to the peritoneal cavity), the circulation time of blood in a mouse is
approximately 8 s.138 This rapid circulation suggests that venous and arterial blood exchanged
~24 times over the course of the scan, allowing for blood solutes (including 1.33) to be exposed
to a relatively high level of oxygen. Therefore, the exchange between venous and arterial blood
during circulation can explain these observations. It is unlikely that dilution alone could account
for the complete loss of observable positive contrast enhancement because no positive contrast
enhancement was observed in organs associated with clearance (liver, kidneys, or bladder;
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Figure 2.2), whereas positive contrast enhancement was observed in the kidneys within 3 min
after intravenous injection of an equivalent dose of 2.1 (Figure 2.3). To ensure that 1.33 had not
been oxidized prior to the injection, T1-weighted images of the syringe were acquired before and
after the injection and observed positive contrast enhancement for both, indicating that oxidation
occurred in vivo.
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Figure 2.2. Representative T1-weighted images demonstrating the response of 1.33 after
different injection types. The images are (A) pre-intravenous injection; (B) 3 min postintravenous injection; (C) 8 min post-intravenous injection; (D) pre-intraperitoneal injection; (E)
3 min post-intraperitoneal injection; (F) 8 min post-intraperitoneal injection; (G) presubcutaneous injection; (H) 3 min post-subcutaneous injection; and (I) 8 min post-subcutaneous
injection. Red arrows denote areas of positive contrast enhancement. The area represented by
each image is 31 mm × 90 mm.
An intraperitoneal injection placed 1.33 into an intermediate pO2 range (relative to
intravenous and subcutaneous injections) and allowed positive contrast enhancement to be
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observed in the 3 min scan. However, the loss of positive contrast enhancement by 8 min
suggests that 1.33 diffused to regions of high oxygen level (vasculature), oxygen diffused into
the peritoneal cavity, or both types of diffusion occurred. Relative to the peritoneal cavity,
subcutaneous space has a lower rate of diffusion and a lower pO2.136,137,139 Consistent with these
properties, positive contrast enhancement was observed both 3 and 8 min post-subcutaneous
injection. Results of the intravenous, intraperitoneal, and subcutaneous imaging experiments
suggest that both pO2 and diffusion play a role in the persistence of EuII-based contrast
enhancement in vivo. Furthermore, despite oxidation occurring in the mice, no adverse effects
were observed during any of the in vivo studies reported here.

Figure 2.3. Structure of GdIII-diethylenetriaminepentaacetate (2.1) used as a non-redox-active
control.
The imaging data presented here demonstrate that 1.33 is oxidized faster than the MRI
timescale used in experiments for intravenous injections, that intraperitoneal injections offer
transitory contrast enhancement, and that subcutaneous injections exhibit positive contrast
enhancement for at least 8 min. These observed trends correlate with reported values of pO2,134–
137

where lower pO2 values correspond to prolonged contrast enhancement. The lack and loss of

positive contrast enhancement observed in the intravenous and intraperitoneal injections,
respectively, inspired the measurement of europium biodistribution, which would be informative
regarding the route of clearance.
To understand the biodistribution of europium for the intravenous and intraperitoneal
injections, inductively coupled plasma mass spectrometry (ICP–MS) was used to quantify
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europium in the blood, liver, kidneys, spleen, heart, bone (femur), muscle (thigh), brain, upper
and lower gastrointestinal tract (GI), stomach, lungs, and brain (Figure 2.4). The majority of
detected europium was found in the liver and kidneys for both types of injections, with the
relative quantities being higher for intravenous injections. ICP–MS data does not provide insight
into speciation during clearance, a complex topic that is currently under investigation using
knowledge of the kinetic stability of EuII/III-containing cryptates;103,130 however, this data
provides valuable insight into the route of clearance. For intraperitoneal injections, the smaller
amount of europium detected in the liver, kidneys, and blood might indicate relatively slow
diffusion from the peritoneal cavity. Evidence of slow diffusion of 1.33 from the peritoneal
cavity supports a response dependent on the diffusion of oxygen into the peritoneal cavity.
Furthermore, the presence of europium in detectable quantities after intravenous injections (there
is no endogenous europium in mice), together with the images in Figure 2.2, suggest that
oxidation of 1.33 occurs within 3 min of intravenous injection.

Figure 2.4. Percent of injected dose of europium retained per organ 1 h post-injection for
intravenous (white bars) and intraperitoneal (black bars) injections. Error bars represent the
standard error of the mean of 3 independent experiments.
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2.4 Conclusions
The results presented in this chapter demonstrate that EuII-based contrast enhancement is
sensitive to the route of administration, with positive contrast enhancement expected for regions
containing relatively low levels of oxygen and slow rates of diffusion. These results help define
the boundaries of EuII-based positive contrast enhancement with 1.33 in vivo, and will likely be
helpful in the preclinical application of other EuII-based complexes. Furthermore, the in vivo use
of lanthanide-based redox-response is a relatively unexplored realm. Although other redox-active
molecules might contribute to the oxidation of EuII, the oxidation of EuII by oxygen is expected
to be responsible for the correlation between oxygen content and the persistence of positive
contrast enhancement in vivo, and efforts in the Allen laboratory to understand aqueous EuII
oxidation chemistry are currently underway. Additionally, biodistribution studies revealed
clearance of europium through the liver and kidneys, but no positive contrast enhancement was
observed in these organs. These results are an important step towards understanding the scope of
EuII-based positive contrast enhancement for a new class redox-active contrast agents based on
lanthanide redox chemistry.
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CHAPTER 3: A EUROPIUM(II)-CONTAINING CRYPTATE AS A REDOX SENSOR IN
MRI OF LIVING TISSUE
Parts of this chapter were adapted with permission from Ekanger, L. A.; Polin, L. A.; Shen, Y.;
Haacke, E. M.; Martin, P. D.; Allen, M. J. Angew. Chem. Int. Ed. 2015, 54, 14398. Copyright ©
2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
3.1 Introduction
MRI is a powerful diagnostic tool for imaging opaque tissues at relatively high spatial
resolution and nearly unlimited depth penetration.21,140 Paramagnetic complexes are routinely
used as contrast agents in clinical MRI to provide contrast enhancement in areas of anatomical
interest. For decades, GdIII has been the paramagnetic metal ion of choice for contrast agents
largely because it has seven unpaired electrons (S = 7/2) in an isotropic ground-state
configuration (8S7/2). EuII is isoelectronic with GdIII, and both ions enhance contrast in MRI.97,124
Furthermore, the EuII center has a propensity to oxidize to EuIII, resulting in a diamagnetic
ground state (7F0) and a thermally accessible excited state (7F1) that do not noticeably enhance
contrast in MRI.73 Therefore, the oxidation of EuII offers the opportunity for metal-based redoxresponsive contrast enhancement that is unachievable with GdIII-based contrast agents. However,
despite several groups exploring EuII-based complexes as contrast agents for MRI,73,97–
99,101,124,126,127,129,131–133

there has been no reported use of EuII in vivo. Herein, first in vivo use of a

EuII-containing cryptate is reported. Characterization that reveals a discrepancy in the
coordination environment of the complex between the solid and solution phases is also
discussed.
3.2 Experimental Procedures
3.2.1 General Procedures
Commercially available chemicals were of reagent-grade purity or better and were used
without further purification unless otherwise noted. Phosphate-buffered saline (10×) was
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purchased from Fisher BioReagents. Water was purified using a PURELAB Ultra Mk2 water
purification system (ELGA) and degassed prior to use. Triethylamine was distilled from CaH2.
Flash chromatography was performed using silica gel 60, 230–400 mesh (EMD
Chemicals). Analytical thin-layer chromatography (TLC) was performed on ASTM TLC plates
pre-coated with silica gel 60 F254 (250 µm thickness). TLC visualization was achieved using UV
irradiation (254 nm) followed by charring with potassium permanganate stain (3 g KMnO4, 20 g
K2CO3, 5 mL 5% w/v aqueous NaOH, 300 mL H2O).
1

13

H- and 13C-NMR spectra were obtained using a Varian MR-400 (400 MHz 1H, 101 MHz

C) spectrometer.

19

F-NMR spectra were obtained using a Mercury 400 (376 MHz

19

F)

spectrometer. Chemical shifts are reported relative to residual solvent signals unless otherwise
noted (CDCl3: 1H: δ 7.27, 13C: δ 77.23; (CD3)2SO: 1H: δ 2.50, 13C: δ 39.52; CD3CN: 1H: δ 1.94,
C: δ 118.26; CFCl3 (internal standard):

13

19

F: δ 0.00). NMR data are assumed to be first order,

and the apparent multiplicity is reported as “s” = singlet, “d” = doublet, “dd” = doublet of
doublets, “ddd” = doublet of doublet of doublets, “t” = triplet, “td” = triplet of doublets, “m” =
multiplet, or “brs” = broad singlet. Italicized elements are those that are responsible for the shifts.
Correlation spectroscopy (COSY), distortionless enhancement by polarization transfer (DEPT),
and heteronuclear multiple quantum coherence (HMQC) spectra were used to assign spectral
peaks. High-resolution electrospray ionization mass spectra (HRESIMS) were obtained on a
Waters LCT premier time-of-flight high-resolution mass spectrometer.
Molar conductivity was calculated from three independently prepared solutions of 3.6
(1.00 mM, 5.00 mL) measured in water under an atmosphere of N2 and ambient temperature
using an Omega CDH 280 portable conductivity meter that was calibrated with aqueous KCl
(0.01 M, 1.413 mS cm–1). Results are reported as mean ± standard error.
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Tumor digestion was accomplished by adding the whole tumor to a solution of nitric acid
(70%, 2 mL) in water (5 mL) in a 25.0 mL volumetric flask. The mixture was heated at 95 °C for
48 h with vigorous stirring to produce a clear, yellow solution. The solution was diluted to 25.0
mL after the removal of the stir bar, and filtered through a 0.2 µm hydrophilic filter. The filtrate
was diluted (1:10) for analysis by inductively coupled plasma mass spectrometry (ICP–MS).
ICP–MS measurements were acquired on an Agilent Technologies 7700 series ICP–MS
instrument at the Lumigen Instrument Center in the Department of Chemistry at Wayne State
University. All dilutions were performed with aqueous 2% HNO3, which was also used for blank
samples during calibration. The calibration curve was created using the

153

Eu isotope ion count

for a 1–200 ppb concentration range (diluted from Fluka ICP standard solution, Eu2O3 in
aqueous 2% HNO3, 1000 mg Eu/L). All samples were diluted to fall within this range.
3.2.2 Synthetic Procedures and Characterization
Scheme 3.1. Synthetic route used to synthesize 3.5.

Dimethyl 2,2’-((4-fluoro-1,2-phenylene)bis(oxy))diacetate (3.2): A mixture of 4fluorobenzene-1,2-diol (3.1, 0.501 g, 3.91 mmol, 1 equiv), acetone (20 mL), potassium carbonate
(2.55 g, 18.5 mmol, 4.7 equiv), and methylbromoacetate (2.11 mL, 22.3 mmol, 5.7 equiv) was
heated at reflux for 2 h, cooled to ambient temperature, and filtered through a fritted funnel
(medium). Solvent was removed from the filtrate under reduced pressure to afford a pale yellow
oil. The oil was dissolved in ethyl acetate (15 mL) and washed with water (3 × 10 mL). The
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organic layer was dried over anhydrous magnesium sulfate before solvent was removed under
reduced pressure to yield 0.986 g (92%) of 3.2 as a pale yellow oil. 1H NMR (400 MHz, CDCl3):
δ = 3.77–3.82 (m, 6H; CH3), 4.68–4.72 (m, 4H; CH2), 6.59–6.67 (m, 2H; FCCH), 6.90 ppm (dd,
3

J(H,H) = 8.8 Hz, 4J(H,F) = 5.4 Hz, 1H; OCCHCH);

13

C NMR (101 MHz, CDCl3): δ = 52.4

(CH3), 52.5 (CH3), 66.5 (CH2), 67.7 (CH2), 103.4 (d, 2J(C,F) = 28.2 Hz, FCCH), 108.3 (d,
2

J(C,F) = 21.2 Hz, FCCH), 117.5 (d, 3J(C,F) = 10.0 Hz, OCCHCH), 144.3 (d, 4J(C,F) = 3.0 Hz),

149.1 (d, 3J(C,F) = 10.5 Hz), 158.3 (d, 1J(C,F) = 241.8 Hz, CF), 169.1, 169.7 ppm;

19

F NMR

(376 MHz, CDCl3, CFCl3): δ = –118.7 to –118.6 ppm (m, F); HRESIMS (m/z): [M + Na]+ calcd
for C12H13O6FNa, 295.0594; found, 295.0594.
2,2’-((4-Fluoro-1,2-phenylene)bis(oxy))diacetic acid (3.3): To a mixture of 3.2 (0.874
g, 3.21 mmol, 1 equiv) and water (25 mL) was added DOWEX (200 mesh, 50W×8, hydrogen
form) resin (0.456 g). The mixture was heated at reflux without stirring for 60 h at which point it
was filtered while hot through Whatman number 1 filter paper. Solvent was removed under
reduced pressure to afford 0.742 g (96%) of 3.3 as an off-white solid. 1H NMR (400 MHz,
(CD3)2SO): δ = 4.65 (s, 2H; CH2), 4.74 (s, 2H; CH2), 6.70 (td, 3J(H,H,F) = 8.6 Hz, 4J(H,H) = 2.9
Hz, 1H; FCCHCH), 6.84 (dd, 3J(H,F) = 10.3 Hz, 4J(H,H) = 2.9 Hz, 1H; FCCHCO), 6.91 (dd,
3

J(H,H) = 8.8 Hz, 4J(H,F) = 5.4 Hz, 1H; OCCHCH), 13.00 ppm (brs, 2H; OH); 13C NMR (101

MHz, (CD3)2SO): δ = 65.1 (CH2), 65.8 (CH2), 102.1 (d, 2J(C,F) = 27.9 Hz, FCCHCO), 106.4 (d,
2

J(C,F) = 24.4 Hz, FCCHCH), 115.2 (d, 3J(C,F) = 10.5 Hz, OCCHCH), 143.8 (d, 4J(C,F) = 3.0

Hz), 148.4 (d, 3J(C,F) = 10.3 Hz), 156.8 (d, 1J(C,F) = 237.4 Hz, CF), 169.9, 170.3 ppm;

19

F

NMR (376 MHz, (CD3)2SO, CFCl3): δ = –119.9 to –119.8 ppm (m, F); HRESIMS (m/z): [M +
Na]+ calcd for C10H9O6FNa, 267.0281; found, 267.0278.
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Diamide (3.4): To 3.3 (0.571 g, 2.34 mmol, 1 equiv) was added thionyl chloride (10 mL,
0.14 mol, 60 equiv) under an atmosphere of Ar. The mixture was heated at reflux for 2 h (the
mixture turned to a clear, yellow solution during this time) before excess thionyl chloride was
removed under reduced pressure to afford a dark yellow oil. The dark yellow oil was dissolved in
anhydrous toluene (50 mL). A separate solution of 4,13-diaza-18-crown-6-ether (0.613 g, 2.34
mmol, 1 equiv), triethylamine (3.0 mL, 22 mmol, 9.4 equiv), and chloroform (7 mL) in
anhydrous toluene (40 mL) was prepared. Both solutions were simultaneously added dropwise
over 1 h to a flask containing anhydrous toluene (500 mL) at 0 °C under an atmosphere of Ar.
After the additions, the reaction mixture was allowed to warm to ambient temperature and was
stirred for 5 h before solvent was removed under reduced pressure. Purification was performed
using silica gel chromatography (8:1 dichloromethane/methanol) to yield 0.646 g (59%) of 3.4 as
a white solid. 1H NMR (400 MHz, CD3CN): δ = 2.69–2.82 (m, 2H; CH2), 3.20–3.33 (m, 2H;
CH2), 3.38–3.77 (m, 18H; CH2), 4.13 (ddd, 2J(H,H) = 14.4 Hz, 3J(H,H) = 4.8 Hz, 3J(H,H) = 2.8
Hz, 1H; CH2CH2), 4.23 (ddd, 2J(H,H) = 14.2 Hz, 3J(H,H) = 6.2 Hz, 3J(H,H) = 2.9 Hz, 1H; CH2),
4.64 (d, 2J(H,H) = 14.7 Hz, 1H; CH2CH2), 4.75 (d, 2J(H,H) = 14.7 Hz, 1H; CH2), 5.27 (d,
2

J(H,H) = 14.7 Hz, 1H; CH2), 5.40 (d, 2J(H,H) = 14.7 Hz, 1H; CH2), 6.60 (td, 3J(H,H,F) = 8.6

Hz, 4J(H,H) = 2.9 Hz, 1H; FCHCH), 6.75 (dd, 3J(H,F) = 10.3 Hz, 4J(H,H) = 2.9 Hz, 1H;
OCCHCF), 6.93 ppm (dd, 3J(H,H) = 8.8 Hz, 4J(H,F) = 5.9 Hz, 1H; OCHCH);

13

C NMR (101

MHz, CD3CN): δ = 48.7 (CH2), 49.0 (CH2), 49.1 (CH2), 49.4 (CH2), 67.8 (CH2), 68.9 (CH2),
69.9 (CH2), 70.0 (CH2), 70.2 (CH2), 70.5 (CH2), 71.5 (CH2), 71.6 (CH2), 71.8 (CH2), 71.9 (CH2),
104.3 (d, 2J(C,F) = 27.1 Hz, OCCHCF), 107.6 (d, 2J(C,F) = 23.2 Hz, FCHCH), 118.7 (d, 3J(C,F)
= 9.9 Hz, OCHCH), 145.4 (d, 4J(C,F) = 3.0 Hz), 150.2 (d, 3J(C,F) = 10.7 Hz), 158.5 (d, 1J(C,F)
= 237.8 Hz, CF), 169.3, 169.6 ppm; 19F NMR (376 MHz, CDCl3, CFCl3): δ = –121.0 to –120.9
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ppm (m, F); TLC: Rf = 0.53 (8:1 dichloromethane/methanol); HRESIMS (m/z): [M + Na]+ calcd
for C22H31N2O8FNa, 493.1962; found, 493.1956.
5,6-(4-Fluorobenzo)-4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacos-5-ene
(3.5): To 3.4 (0.549 g, 1.17 mmol, 1 equiv) was added borane tetrahydrofuran complex (1.0 M,
35.0 mL, 35.0 mmol, 30 equiv) under an atmosphere of Ar. The solution was heated at reflux for
23 h before the reaction was allowed to cool to ambient temperature. To the reaction solution
was slowly added hydrochloric acid (3.0 M, 50 mL, 15 mmol, 13 equiv) over 10 min, and the
resulting white, turbid mixture was heated at reflux for 3 h to form a clear, colorless solution
before it was allowed to cool to ambient temperature. The pH of the reaction solution was
adjusted to 11 with the addition of concentrated ammonium hydroxide (20 mL) before solvent
was removed under reduced pressure to afford a white solid. Purification was achieved using
silica gel chromatography (8:1 dichloromethane/methanol) to yield a white oily solid that was
dissolved in a concentrated cesium carbonate solution (pH <10) and extracted with chloroform (3
× 15 mL). The organic layers were combined, dried over anhydrous magnesium sulfate, filtered
through a fine glass frit, and solvent was removed under reduced pressure to yield 0.417 g (81%)
of 3.5 as a colorless oil. 1H NMR (400 MHz, CDCl3): δ = 2.68–2.79 (m, 8H; CH2), 2.90 (t,
3

J(H,H) = 6.4 Hz, 2H; CH2), 2.95 (t, 3J(H,H) = 5.4 Hz, 2H; CH2), 3.51–3.68 (m, 16H; CH2),

4.05–4.13 (m, 4H; CH2), 6.56 (td, 3J(H,H,F) = 8.6 Hz, 4J(H,H) = 2.9 Hz, 1H; FCCHCH), 6.62
(dd, 3J(H,F) = 9.8 Hz, 4J(H,H) = 2.9 Hz, 1H; FCCHCO), 6.82 ppm (dd, 3J(H,H) = 8.8 Hz,
4

J(H,F) = 5.4 Hz, 1H; OCHCH); 13C NMR (101 MHz, CDCl3): δ = 55.1 (CH2), 55.4 (CH2), 56.1

(CH2), 56.4 (CH2), 68.1 (CH2), 69.8 (CH2), 70.2 (CH2), 70.4 (CH2), 70.9 (CH2), 71.2 (CH2),
102.8 (d, 2J(C,F) = 26.5 Hz, FCCHCO), 106.6 (d, 2J(C,F) = 21.7 Hz, FCCHCH), 117.2 (d,
3

J(C,F) = 10.8 Hz, OCHCH), 145.4 (d, 4J(C,F) = 2.4 Hz), 150.7 (d, 3J(C,F) = 10.8 Hz), 158.0

60

ppm (d, 1J(C,F) = 238.3 Hz, CF);
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F NMR (376 MHz, CDCl3, CFCl3): δ = –120.2 to –120.0

ppm (m, F); TLC: Rf = 0.32 (8:1 dichloromethane/methanol); HRESIMS (m/z): [M + Na]+ calcd
for C22H35N2O6FNa, 465.2377; found, 465.2384.
3.2.3 Preparation of Solutions Containing 3.6
Contrast agent solutions were prepared by adding aqueous EuCl2 (100.5 µL, 199.1 mM)
and aqueous 3.5 (379.5 µL, 52.7 mM) in a 1:1 stoichiometry to 420.0 µL water in a 4 mL glass
vial equipped with a magnetic stir bar under an inert atmosphere. The resulting clear, colorless
solution was stirred for 1 h before addition of degassed 10× phosphate-buffered saline and water
to achieve a solution of 3.6 (approximate concentration of 20 or 10 mM) in phosphate-buffered
saline (11.9 mM phosphates, 137 mM sodium chloride, 2.7 mM potassium chloride, pH 7.4).
The clear, colorless solution was stirred for 30 min then filtered through a 0.2 µm hydrophilic
filter (uncomplexed EuII precipitates as phosphate salts).98 Solutions for T1 mapping and

17

O-

NMR studies were prepared in the same manner. Eu concentrations after filtration were
determined by ICP–MS to be 19.4 and 6.9 mM for 3.6 used for injections; 0.93, 0.64, and 0.32
mM 3.6 used for T1 mapping; and 9.58 mM 3.6 used for 17O-NMR studies.
X-ray quality crystals of 3.6 were prepared by dissolving EuCl2 (7.2 mg, 0.032 mmol, 1
equiv) and 3.5 (19 mg, 0.043 mmol, 1.3 equiv) in methanol (0.25 mL) under an atmosphere of
N2. The resulting clear, yellow solution was stirred for 1 h before the addition of tetrahydrofuran
(3.0 mL). Solvent was slowly evaporated to afford pale yellow needle-like crystals.
3.2.4 Animal Models
Studies in animals were carried out with the assistance of the Animal Model and
Therapeutics Evaluation Core of the Barbara Ann Karmanos Cancer Institute after approval from
the Wayne State University Institutional Animal Care and Use Committee. Methods of protocol
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design, toxicity evaluation, drug treatment, and use of transplantable tumor model systems have
been previously reported.141,142 A brief description of the methods as they apply to this work is as
follows: Female BALB/cAnNCr mice (National Cancer Institute Animal Breeding Program;
Charles River) were implanted with the syngeneic murine mammary tumor model 4T1.143
Tumors were maintained in the mouse strain of origin (BALB/c) and housed in animal facilities
accredited by the Association for Assessment and Accreditation of Laboratory Animal Care with
24/7 veterinary oversight of care and husbandry. Animals were pooled, implanted bilaterally
subcutaneously with 30–60 mg tumor fragments with a 12 gauge trocar, and imaged when
tumors reached approximately 700–1000 mg in size (determined by caliper measurements: tumor
mass (mg) ≈ [tumor length (mm) × tumor width2 (mm2)]/2). All mice were a minimum of 18 g
before entering the study and were provided food and water ad libitum.
3.2.5 Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) was performed using a 7 T Bruker Clinscan small
animal MRI scanner with a 30 cm bore in the MR Research Facility at Wayne State University.
Whole body coronal plane images were acquired using a 3D FLASH sequence with an echo time
of 1.5 ms, repetition time of 11 ms, flip angle of 40°, 44 image slices at 0.5 mm thickness, a 30
mm × 90 mm field of view, and an in-plane resolution of 0.352 mm × 0.352 mm.
Imaging studies were performed with female tumor bearing BALB/cAnNCr mice.
Animals were first anesthetized (1.5–2% v/v isoflurane in oxygen) and immobilized on a bed
heated by circulating temperature-controlled water (37 °C). Mice were imaged before injections,
briefly removed from the magnet (while still stably positioned on the bed), injected, then
returned to the magnet imaged immediately to acquire the first time point (3 min) post-injection
and imaged again at a subsequent times of 20 and 120 min post-injection. Intratumoral injections
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were performed using tuberculin syringes (1 mL) fitted with 27 gauge × 0.5 in. needles. After all
necessary measurements and images were obtained, animals were immediately humanely
euthanized. Flank tumors were removed immediately and placed directly into 10% buffered
formalin for histology or dissolved nitric acid for analysis of Eu content.
3.2.6 Histology
Fixed tissue paraffin embedding, hematoxylin and eosin staining, paraffin sectioning, and
optical microscopy of stained sections were performed at the Biobanking and Correlative
Sciences Core of the Barbara Ann Karmanos Cancer Institute.
3.2.7 Relaxivity Data
T1 maps were acquired using a published procedure for the accurate determination of T1
in the presence of radiofrequency-field inhomogeneities and flip-angle miscalibration.144 The
relaxivity plots were triplicated measurements of independently prepared samples (Figure S1).
The slopes of the relaxivity plots were used to calculate the mean relaxivity plus or minus the
standard error of the mean.

Figure 3.1. Longitudinal relaxation rate vs 3.6 concentration in phosphate-buffered saline.
3.2.8 17O-NMR Spectroscopy Data
Variable-temperature

17

O-NMR measurements of 3.6 (9.58 mM) in phosphate-buffered

saline (pH = 7.4) and a pH = 7.4 blank of phosphate buffered saline were obtained on a Varian500S (11.7 T) spectrometer.

17

O-enriched water (20% H217O, Cambridge Isotope Laboratories,
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Inc.) was added to samples to achieve 1% enrichment in

17

O. Line widths at half height were

measured at 30, 40, 50, 60, and 70 °C. The 17O-NMR data are presented in Table 3.1.
Table 3.1. 17O linewidths for 3.6 and phosphate buffer as a function of temperature.
Temperature (°C)

Linewidth (Hz)
3.6

phosphate buffer

70

45

30

60

57

35

50

77

42

40

103

53

30

144
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3.2.9 Crystallographic Data
Crystal structure analysis was performed on a Bruker APEX-II Kappa geometry
diffractometer with Mo radiation and a graphite monochromator using a Bruker charge coupled
device based diffractometer equipped with an Oxford Cryostream low-temperature apparatus.
The data was measured at a temperature of 100 K. The structure was solved by the direct method
using the SHELXS-97 program that is part of APEX II2 and refined by the least squares method,
SHELXL 2012 incorporated into ShelXle.5 Single crystals of 3.6 contained one cation composed
of the complex with a single coordinated chloride and one outer sphere chloride counter ion in
the asymmetric unit. The structure was solved with a resolution of 0.59 Å in space group
P121/n1. All non-hydrogen atoms were refined anisotropically. CCDC 1415606 contains the
supplementary crystallographic data for this paper. These data are provided free of charge by
The Cambridge Crystallographic Data Centre.
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Table 3.2. Crystallographic properties of 3.6.
Chemical formula

C22H35Cl2EuFN2O6

Formula weight

665.38

Temperature

100(2) K

Wavelength

0.71073 Å

Crystal system

monoclinic

Space group

P 1 21/n 1

Unit cell dimensions

a = 10.6274(9) Å

α = 90°

b = 17.8644(14) Å

β = 99.036(4)°

c = 13.6797(12) Å

γ = 90°

Volume

2564.9(4) Å3

Z

4

Density (calculated)

1.723 g cm–3

Absorption coefficient 2.701 mm–1
F(000)

1340

3.3 Results and Discussion
Complex 3.6 (Figure 3.2) was chosen for in vivo imaging because it has a relatively
positive oxidation peak potential (0.366 V versus the normal hydrogen electrode).101 More
positive potentials favor the 2+ oxidation state that is desirable for imaging. However, 3.6 is
prone to oxidation by molecular oxygen, and the EuII ion in this cryptate was expected to be
oxidized to the EuIII ion in tissues containing appreciable levels of molecular oxygen or other
strong oxidants. In healthy tissue, intracellular environments tend to be reducing whereas
extracellular environments tend to be oxidizing, but in necrotic tissue, dead cells leach
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components of the cytosol into the extracellular space to create a relatively reducing
environment.145,146 It was hypothesized that the reducing environment of necrotic tissue would
prevent oxidation of 3.6 and, consequently, contrast enhancement would be observed in necrotic
tissue in the presence of 3.6. Before imaging in vivo, 3.6 was characterized using solid- and
solution-phase techniques.

Figure 3.2. (a) Proposed solution-phase structure of 3.6 with non-coordinated chloride
counteranions and one or two coordinated water molecules (n = 1 or 2). (b) X-ray crystal
structure of 3.6 with a coordinated chloride ion (hydrogen atoms and the outer sphere chloride
counteranion are not shown for clarity). R-factor = 0.0248. Resolution = 0.59 Å. Thermal
ellipsoids are drawn at the 50% probability level.
The X-ray crystal structure of 3.6 (Figure 3.2) features a nine-coordinate metal center in
an eclipsed hula-hoop geometry.147 Eight coordination sites are occupied by six oxygen and two
nitrogen atoms of 3.5 and the ninth site is occupied by a coordinated chloride counteranion.
Interestingly, this nine-coordinate geometry is different than the ten-coordinate geometry of a
SrII-containing [2.2.2] cryptate (without the fluorobenzo group) that contains a coordinated water
molecule and coordinated trifluoromethanesulfonate anion.127 This difference is noteworthy
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because SrII and EuII have similar ionic radii, and SrII is often used as a diamagnetic analog for
EuII. Because coordination environment is a key parameter in the characterization of contrast
agents for MRI, the coordination environment of 3.6 in was interrogated in solution.
To test whether chloride remained coordinated in solution, molar conductivity of 3.6 in
water was measured. The molar conductivity was 211 ± 1 S cm2 mol–1, which is consistent with
compounds exhibiting a 2:1 dissociation in water.148 This observation indicates that, on average,
no chlorides are coordinated to EuII in solution. However, because molar conductivity is a
colligative property, it does not provide further information regarding the coordination
environment of 3.6 in solution.
To further characterize the coordination environment of 3.6 in solution, variabletemperature

17

O-NMR spectroscopy was used to investigate water coordination. Using 1%

enriched H217O in phosphate-buffered saline, paramagnetic broadening of the

17

O-NMR signal

upon addition of 3.6 was observed. The line broadening is consistent with the presence of inner
sphere water. This observation coupled with a 2:1 dissociation suggests that in solution 3.6 is
present either as a nine-coordinate species with chloride displaced by a water molecule or as a
ten-coordinate species, based on the ability of EuII to adopt ten-coordinate geometries,149 with
two coordinated water molecules after chloride dissociation (Figure 3.3). It is unlikely that more
than two water molecules coordinate because 3.5 occupies eight coordination sites and because
to the best of my knowledge, no eleven-coordinate molecular EuII-containing complexes have
yet been reported. After studying the coordination environment of 3.6, in vitro MRI was used to
characterize its ability to influence contrast.
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Figure 3.3. (a) X-ray crystal structure (viewed along the N–Eu–N axis) of 3.6 (hydrogen atoms
are not shown for clarity) alongside a cartoon representation of the solid-phase geometry in the
same orientation as the crystal structure. Outer sphere chloride, Cl00, related by symmetry is
included in the image. (b) Cartoon representation of the proposed solution-phase geometry of 3.6
with one or two coordinated water molecules viewed along the N–Eu–N axis. The blue and teal
spheres in the cartoons represent nitrogen and europium, respectively, and the bold lines
represent the cryptands. R-factor = 0.0248. Resolution = 0.59 Å. Thermal ellipsoids are drawn at
the 50% probability level.
To characterize the ability of 3.6 to provide contrast enhancement, the relaxivity of 3.6 in
phosphate-buffered saline was measured using T1-weighted MRI. The relaxivity (24 °C, 7 T) of
3.6 in phosphate-buffered saline was 6.5 ± 0.3 mM–1 s–1. This relaxivity value in phosphatebuffered saline is in agreement with other EuII-containing cryptates.97 Additionally, phosphate
can bind lanthanide ions in a bidentate manner to displace two water molecules when the metal
ion contains two adjacent coordinated water molecules.150 Nonadjacent water would be
consistent with water molecules replacing the two chloride ions (Figure 3.3). While not
coordinated, the outer sphere chloride is 5.383 Å from EuII (the coordinated chloride is 2.793 Å
from EuII), and if both chloride ions are replaced by water molecules, a closer approach could be
envisioned due to the smaller size of oxygen relative to chloride. Accordingly, the

17

O line

broadening, crystal structure, and relaxivity suggest that if two water molecules are coordinated
to 3.6 in solution, that they are likely not adjacent to each other.
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To test whether 3.6 would enhance contrast in necrotic tissue, T1-weighted MRI was
performed before and after intratumoral injection of 3.6 (50 µL, 19.4 mM) into a 4T1 mammary
carcinoma. The 4T1 carcinoma model is an aggressive tumor that typically develops a necrotic
core,151 and imaging was performed when tumors reached approximately 700–1000 mg to
maximize the probability of necrosis. Images were acquired before and at 3, 20, and 120 min
after intratumoral injection (Figure 3.4). Positive contrast enhancement was observed for the
entirety of the 120 min experiment, but the location of positive contrast enhancement changed
over time. Specifically, heterogeneous positive contrast enhancement was observed along nearly
the entire length of the tumor immediately post injection, but was only observed in a localized
core of the tumor after 120 min. These observations demonstrate that Eu II persists within a tumor
for at least 120 min, and this duration of positive contrast enhancement was consistent in all
seven of the attempted imaging experiments with independently injected tumors. The presence of
contrast enhancement is consistent with the persistence of the 2+ oxidation state of europium in
the core of the tumor, and the reduced oxidation state is suggestive of a lack of oxygen.
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Figure 3.4. T1-weighted in vivo sagittal plane images of a 4T1 tumor injected with 3.6 (a) preinjection; (b) 3 min, (c) 20 min, and (d) 120 min post-intratumoral injection; (e) difference
between the 120 min and pre-injection images (image d minus image a) colored using the ImageJ
green lookup table; (f) hematoxylin- and eosin-stained slice of tumor imaged in a–e; and (g) sum
of images e and f. All images are on the same scale. Imaging parameters included an echo time
of 1.5 ms, repetition time of 11 ms, flip angle of 40°, field of view of 30 mm × 90 mm, and an
in-plane resolution of 0.352 mm × 0.352 mm.
To verify the presence of necrotic tissue in the tumor, the mouse was sacrificed directly
after the 120 min post-injection image and performed histological staining. The tumor was
removed in whole, fixed in formalin, mounted in paraffin, and cut to a thickness of 5 µm before
being stained with hematoxylin and eosin (Figure 3.4). Hematoxylin is a dye that stains nuclei,
and eosin stains elements of the cytoplasm as a counterstain to differentiate areas that are nucleiabundant (blue) from those that are nuclei-deficient (pink).152 Areas associated with necrosis are
expected to stain pink to a greater extent than non-necrotic areas because of the lack of cells and
their corresponding nuclei in necrotic regions. The stained slice revealed nuclei-deficient regions
consistent with necrosis that were particularly pronounced in the mid-to-upper half of the tumor.
The leftmost region of the slice stained pink from the presence of tumor ulceration through the
mouse epidermis. Consistent with staining, the majority of positive contrast enhancement

70

observed 120 min post-injection was in the mid-to-upper half of the tumor, suggesting that 3.6
provided positive contrast enhancement in the necrotic core of the tumor (Figure 3.4). No
contrast enhancement was observed in the leftmost region of the tumor likely because of direct
contact between tumor ulceration and oxygen in the air. It is worth reiterating that an
intratumoral injection was used, which may have placed a bolus in the tumor core and the lack of
oxygen allowed EuII to persist.
To better understand the potential mechanism of differentiation, an intratumoral injection
of 3.6 (50 µL, 6.9 mM) was performed and contrast enhancement was monitored over the course
of 3 h before sacrificing the mouse and removing the injected tumor for analysis of Eu content
by inductively coupled plasma mass spectrometry. At 3 h post-injection, a decrease in positive
contrast enhancement (~85%) was observed in the tumor relative to the initial image and a
decrease of in the Eu content (~80%) was observed in the tumor relative to the injected dose.
These close values suggest clearance of 3.6 played a major role in the loss of positive contrast
enhancement. Clearance was not directly observed in T1-weighted MRI because 3.6 likely
oxidized in tissues or fluids of relatively higher oxygen content, and the product of oxidation,
EuIII, does not produce positive contrast enhancement. Furthermore, when 3.7 (Figure 3.5) (50
µL, 20.5 mM) was injected into a tumor in a separate experiment, the bladder of the mouse was
bright with contrast within minutes of the injection. This phenomenon was observed in two
independently injected tumors. This non-redox-active control indicates that the concentration of
EuII injected should be enough to visualize in the bladder if clearance occurred without
oxidation. The evidence of clearance based on Eu content and the lack of contrast enhancement
observed outside of the tumor demonstrates the lack of background enhancement possible with
EuII-based imaging agents in redox-active environments. While the connection between positive
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contrast enhancement and necrotic tissue is intriguing, more detailed experiments are required to
evaluate the nature of 3.6 clearance over time. Regardless of the mechanism of differentiation,
these in vivo imaging data demonstrate the first reported use EuII for in vivo contrast-enhanced
MRI.

Figure 3.5. Structure of GdIII-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (3.7).
To investigate the in vitro stability of 3.6 with respect to oxygen exposure, T1 (37 °C, 1.4
T) of 3.6 was measured in phosphate-buffered saline to monitor the oxidation of EuII as a
function of air exposure while stirring. Under an atmosphere of N2 (pO2 ≈ 0 mmHg), 3.6
remained in the 2+ oxidation for at least 118 d. However, upon stirring in open air (pO2 ≈ 160
mmHg), the observed T1 enhancement was completely lost within 5 min. This rapid oxidation
with elevated oxygen exposure suggests that 3.6 is oxidized upon clearance from the oxygendeficient 4T1 necrotic core (pO2 ≤ 10 mmHg)134,135 into relatively oxygenated vasculature (pO2 ≈
40–100 mmHg).136 Collectively, the persistence of the 2+ oxidation state over a 120 min period,
the correlation between necrotic tissue and contrast enhancement, the lack of positive contrast
enhancement in organs associated with clearance (bladder, liver, or kidneys), and the rapid
oxidation observed in elevated air exposure suggest that 3.6 persists in the poorly oxygenated
necrotic core of the tumors and oxidizes elsewhere.
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3.4 Conclusions
Solid- and solution-phase characterization of 3.6 indicated that the complex is ninecoordinate in the solid state and nine- or ten-coordinate in solution. The ability to differentiate
necrotic from non-necrotic tissue in vivo coupled with the tunable oxidation potential of EuII is
expected to enable bracketing of tissue redox environments associated with both hypoxic and
hyperoxic tissues relevant to the study of many diseases.
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CHAPTER 4: OXIDATION-RESPONSIVE EUROPIUM(II/III)–LIPOSOMAL
CONTRAST AGENT FOR DUAL-MODE MRI
Parts of this chapter were adapted with permission from Ekanger, L. A.; Ali, M. M.; Allen, M. J.
Chem. Commun. 2014, 50, 14835. Reproduced by permission of The Royal Society of
Chemistry.
4.1 Introduction
The power of MRI resides in the ability to ascertain anatomical information at high
resolution for clinical (1 mm isotropic) and preclinical (0.025 mm isotropic) applications.153
Molecular information can also be obtained with MRI using responsive paramagnetic complexes
(contrast agents) that alter water proton signal intensities in response to chemical events. Some
contrast agents respond to changes in pH,40–42,154–156 temperature,59,61,157 metal ion
concentration,35,63,65 enzyme activity,33,158,159 or partial pressure of oxygen,66 the presence of free
radicals,72,160 antioxidants,68 phosphate diesters,161 singlet oxygen,70 reduced glutathione and
hydrogen peroxide,71 or oxygen, dithionite, and cysteine.69 Of particular interest are targets that
cause changes in redox behavior because they are associated with cancer,109,111 inflammation,162
and cardiovascular diseases.113 Accordingly, responsive contrast agents that target redox changes
have the potential to greatly improve the diagnostic capabilities of MRI. However, a critical
limitation of responsive contrast agents that hinders their use in vivo is that determination of
molecular information requires knowledge of the concentration of contrast agent, which is
exceedingly difficult to measure in vivo. Some systems have achieved concentration
independence in contrast-enhanced MRI through ratiometric techniques (longitudinal vs
transverse relaxation rates),50 ratiometric chemical exchange saturation transfer (CEST)
techniques,70,154 or the use of orthogonal detection modes with a multimodal agent;163 however,
to the best of my knowledge, no reported system demonstrates a concentration-independent
response to general oxidizing events based on tunable oxidation potentials. An ideal metal ion
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for multimodal redox response is EuII because the EuII and EuIII oxidation states orthogonally
enhance T1-weighted and CEST images, respectively, in MRI. Furthermore, EuII has a tunable
oxidation potential101 and outperforms clinically approved T1-shortening contrast agents at ultrahigh magnetic field strengths.97,98 To address the need for a concentration-independent,
oxidation-responsive contrast agent, it was hypothesized that encapsulating 1.33 in liposomes
(Figure 4.1) would produce an oxidation-responsive dual-mode contrast agent because it would
enhance either T1-weighted images or CEST images depending on the oxidation state of Eu.
The response to oxidation was based on the oxidation of EuII to EuIII because these two
oxidation states offer orthogonal modes of detection by MRI and the EuII/III oxidation state
switch offers an ideal platform for oxidation-responsive contrast enhancement.66,127 The use of
this switch has awaited sufficient stabilization of EuII that the Allen laboratory demonstrated
through modifications to 1.33 ligand structure.101 Furthermore, changes to ligand structure made
the corresponding oxidation potential of EuII tunable over a physiologically relevant range.101
Here, the encapsulation of 1.33 in liposomes and distinct oxidation-responsive, dual-mode
imaging behavior is reported. This system is expected to open the door for concentrationindependent diagnostic imaging of redox-active disease states using the chemistry of Eu.

Figure 4.1. Representation of the oxidation of liposome-encapsulated 1.33 (T1 enhancement and
CEST effect) to form liposomes containing 4.1 (T1 silent with CEST effect). On the far right is a
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depiction of the liposomal phospholipid bilayer with ovals as cholesterol molecules. For clarity,
only one complex is shown in each liposome and coordinated water molecules are not drawn.
4.2 Experimental Procedures
Commercially available chemicals were of reagent-grade purity or better and were used
without further purification unless otherwise noted. Water was purified using a PURELAB Ultra
Mk2 water purification system (ELGA) and degassed prior to use. NMR spectroscopy and
inductively coupled plasma optical emission spectroscopy (ICP–OES) analyses were performed
at the Lumigen Instrument Center in the Department of Chemistry at Wayne State University and
in the Department of Chemistry at Oakland University. In vitro phantom imaging was performed
at Henry Ford Hospital.
Inversion-recovery T1 measurements were obtained using a Varian VNMRS 500 (499.48
MHz, 11.7 T) spectrometer before air exposure or after 24 h of air exposure. Deuterium oxide
(300 mOsm NaCl) was added to make liposome suspensions 5% D2O (v/v) for the purpose of
locking and shimming.
4.2.1 Phantom Imaging
MRI scans were performed with a 7 T Varian small animal MRI scanner (299.44 MHz,
7.0 T) equipped with a 12 cm bore magnet and a 38 mm diameter homemade transmit/receive
quadrature birdcage coil. Samples included liposomes that were not exposed to air, liposomes
that were exposed to air for 24 h, and water. The T1-weighted images were acquired at ambient
temperature (echo time: 11 ms; repetition time: 320 ms; seven image slices at 1 mm thickness;
24 × 24 mm field of view; and four averages). The liposome-encapsulated EuIII (chemical
exchange saturation transfer, CEST) effects were measured at ambient temperature under the
same parameters used in a previous CEST MRI study.164 A RARE MRI pulse sequence with a
RARE factor of 8 (repetition time/echo time, 4.0 s/11 ms) was applied with a 17 μT saturation
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power for 2 s. A total of 64 s was required to acquire a single MR image with 128 × 128 pixels
that covered a 24 × 24 mm field of view, a single slice with a thickness of 1 mm, and a single
average. The water signal was measured for each phantom when saturation was applied between
5 and –5 ppm in 0.2 ppm increments to measure the CEST effect of liposomes, and CEST
images were generated by subtracting images acquitted at 1.2 ppm (SΔω) and –1.2 ppm (S–Δω).
Varian flexible data format (FDF) files were converted to tagged image file format
(TIFF) files with a MATLAB code.165 TIFF files were processed to produce chemical exchange
saturation transfer (CEST) spectra by measuring pixel intensities with ImageJ 1.47.166 Percent
CEST (%CEST) was calculated using Eq 4.1.167
Eq 4.1.

𝑀

%CEST = (1 − 𝑀𝑧 ) 100
0

In Eq 4.1, MZ and M0 are the average signal intensities (calculated with ImageJ) of the
same phantom tube slice at 360 Hz (1.2 ppm) and –360 Hz (–1.2 ppm), respectively. The CEST
image was created by subtracting the TIFF slice at 360 Hz (1.2 ppm) from the identical slice at –
360 Hz (–1.2 ppm) and the difference was divided by the slice at 360 Hz (–1.2 ppm).
The %CEST scale bar was created by calibrating the pixel range of the CEST image to the
maximum %CEST value obtained from Eq 4.1 using a linear fit.
4.2.2 Dynamic Light Scattering
Dynamic light scattering data were obtained using a Malvern Zetasizer Nano-ZS
instrument (ZEN3600) operating with a 633 nm wavelength laser. Dust was removed from
samples by filtering through 0.2 μm hydrophilic filters (Millex–LG, SLLGR04NL). Liposome
samples were prepared for light scattering experiments by diluting purified liposome suspensions
in iso-osmolar phosphate-buffered saline (PBS, 1:10, 29 mM Na2HPO4, 46 mM NaH2PO4, 57
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mM NaCl, and 2.1 mM KCl). For liposome size measurements with no air exposure, air-tight
cuvettes were filled in a glovebox under an atmosphere of Ar.
4.2.3 Elemental Concentration Measurements
ICP–OES measurements were acquired on a Jobin Yvon Horiba Ultima or PerkinElmer
Optima 7000 DV spectrometer. All samples were diluted with 2% HNO3, which was also used
for blank samples during calibration. The calibration curves were created using the Eu emission
intensity at 381.965 nm for a 1–60 ppm concentration range (diluted from Alfa Aesar Specpure
AAS standard solution, Eu2O3 in 5% HNO3, 1000 μg/mL) and the Sr emission intensity at
407.771 nm for a 0.5–5 ppm concentration range (diluted from Fluka Analytical Sr ICP standard,
1000 mg/L), and all samples were diluted to fall within the concentration range of standards for
the respective element.
4.2.4 Preparation of Hydration Solution
The hydration solution was prepared by stirring an aqueous solution of EuCl2 and
4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane for 12 h under an atmosphere of
Ar followed by a phosphate-buffer-workup.98 To account for loss of phosphate during the
precipitation step of this experiment, a PBS stock solution was prepared with a high
concentration of phosphate (1 M). The purpose of the high phosphate concentration was to
ensure PBS buffer capacity was not lost upon phosphate precipitation in the presence of
uncomplexed EuIII in the oxygen-exposed samples and to maintain physiological osmolality (300
mOsm). This PBS solution was prepared in a glovebox under an atmosphere of Ar by dissolving
anhydrous dibasic sodium phosphate (42.6 g, 0.300 mol), monobasic sodium phosphate
monohydrate (27.6 g, 0.200 mol), sodium chloride (22.3 g, 0.381 mol), and potassium chloride
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(1.01 g, 13.6 mmol) in H2O (500 mL). The pH of the resulting solution was brought to 7.0 with
the addition of solid sodium hydroxide (3.87 g, 96.8 mmol).
To a 4 mL glass vial equipped with a magnetic stir bar was added aqueous EuCl2 or SrCl2
and aqueous ligand under an atmosphere of Ar to form 1.33 or 4.2 (Figure 4.2), respectively.
The resulting clear, colorless solution was stirred for 12 h before addition of the PBS solution
described above (390 mM Na2HPO4, 610 mM NaH2PO4, 762 mM NaCl, 27.2 mM KCl, pH 7.0)
and water to bring the osmolality of the solution to 300 mOsm. Upon addition of PBS, a slightly
turbid suspension formed that was stirred for 1 h and then filtered through a 0.2 μm hydrophilic
filter. The final concentrations of Eu (13, 24, 40 and 45 mM) or Sr (28 mM) of the clear,
colorless filtrates were determined by ICP–OES. This filtrate was used for liposome preparation.
The hydration solution used to prepare blank liposomes consisted of iso-osmolar (300 mOsm)
PBS prepared by dilution of the PBS solution described above.

Figure 4.2. Structure of the diamagnetic control 4.2.
4.2.5 Preparation of Liposomes
Liposomes were prepared via the thin-film hydration technique.51 To a 4 mL vial was
added 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (4.3 in Figure 4.3) (22.0 mg, 2.89
μmol, 1.4 equiv), cholesterol (4.4 in Figure 4.3) (8.0 mg, 2.1 μmol, 1 equiv), and chloroform (1
mL) to produce a clear, colorless solution. Avoid exposing the lipids to air for extended periods
of time because they tend to be hygroscopic. It is advisable to partition lipids into vials, remove
air and moisture under reduced pressure on a Schlenk line, and backfill multiple times with Ar

79

before returning to extended storage in the freezer. Removing air and moisture and storing under
Ar will increase the longevity of lipids that are hygroscopic and prone to oxidation or hydrolysis.
Solvent was removed under reduced pressure to afford a visible film on the bottom of the vial.
Under an atmosphere of Ar, the hydration solution (1.15 mL) and vial containing the lipid thin
film were placed in a water bath at 55 °C for 30 min, and then the hydration solution was added
to the vial containing the thin film. The resulting white suspension was stirred at 55 °C for 1 h.
Extrusion of the suspension was accomplished using a mini-extruder and heating block (Avanti
Polar Lipids, Alabaster, AL, USA) heated to 55 °C (4 passes through a 0.2 μm polycarbonate
filter followed by 15 passes through a 0.1 μm polycarbonate filter). Do not apply too much
pressure when extruding liposomes suspensions as the glass syringes are somewhat fragile.
Ensure that the syringes are not clogged prior to use, and never clean them with anything other
than water, aqueous detergent, or isopropanol. After extrusion, the suspension was allowed to
cool to ambient temperature within the Ar-filled glovebox for 1 h. To prevent clogged
equipment, clean out the syringes and filter assembly immediately after use.

Figure 4.3. Structures of 4.3 and 4.4.
Non-encapsulated MII-containing cryptate (M = Eu, Sr) was removed from the liposome
suspension in an Ar-filled glovebox via spin filtering (Amicon Ultra regenerated cellulose 3,000
molecular weight cut off). The liposome suspension was filtered in aliquots because the volume
of the suspension exceeded the volume of the spin filter. When the volume of suspension in the
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filter reached 0.3 mL after spinning, the volume was brought to 0.5 mL with the addition of isoosmolar (300 mOsm) PBS prepared by dilution of the PBS solution described above. The filtrate
fractions (150 µL each) were collected until Eu or Sr was not detectable by ICP–OES (~17
fractions). It should be noted that the rate of filtration decreases as the volume of the liposome
suspension decreases and that the liposome suspension is naturally slow to filter because it is
relatively concentrated. For these two reasons, the spin filtering process is relatively lengthy
(collecting 17 fractions may require up to 24 h). One cannot simply leave the filtration
unattended for extended periods of time and expect expedient results. This process will require 2
or 3 days, depending on length of time in lab, of adding PBS every 20 minutes. If filtrate is not
observed during spin filtering, a centrifuge capable of higher rotations per minute is advised. I
found that a Fisher Scientific Mini Centrifuge (Catalog number 05-090-100) worked sufficiently,
while a GeneMate Bioexpress Mini Centrifuge (Catalog number C-1301-PC) did not work well
for spin filtering liposome suspensions. Adding a small amount of PBS every 20 minutes helped
to keep the filtration going smoothly. Accordingly, it is important to plan for 2 or 3 days of spin
filtering alone before scheduling imaging time or before sending samples out to collaborators. It
may be advantageous to screen spin filters with larger molecular weight cut off thresholds. Spin
filtering was also attempted using 10,000 molecular weight cut off filters, but the rate of
filtration did not appear to improve. Using a relatively high molecular weight cut off filter that
still retains liposomes could potentially expedite the process. The spin filtering process is
tedious, but there is an alternative. Exhaustive dialysis could be used in theory, but would require
the degassing of copious amounts of pure water (~3 L water per liposome batch depending on
the amount of material to be purified) to bring into the glovebox. Additionally, a large amount of
degassed PBS would be required to maintain an appropriate salt concentration of the outer
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solution to prevent an osmotic pressure gradient from damaging the liposomes. Spin filtering was
chosen because it is resource efficient.
4.2.6 CEST Imaging Data
In vitro phantom image intensities were plotted as a function of frequency offset of
presaturation for blank liposomes, liposomes containing 28 mM 4.2, liposomes containing 13
mM 1.33, liposomes containing 24 mM 1.33, liposomes containing 40 mM 1.33, and liposomes
containing 45 mM 1.33 (Figure 4.4). These data were used for Lorentzian curve fitting.
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Figure 4.4. CEST spectra (7 T, ambient temperature) of raw image intensity data before (hollow
circles) and after (solid circles) air exposure of (a) blank liposomes, (b) liposomes containing 28
mM 4.2, (c) liposomes containing 13 mM 1.33, (d) liposomes containing 24 mM 1.33, (e)
liposomes containing 40 mM 1.33, and (f) liposomes containing 45 mM 1.33.
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4.2.7 Lorentzian Function Fitting
The raw CEST imaging data before and after air exposure was modeled with
Mathematica 9.0 using a sum of two Lorentzian functions (Eq 4.2) optimized with least squares
fitting.
Eq 4.2

𝑦=

𝑎1 𝑘1
2

𝑘1 +(𝑥−𝑥1

)2

+

𝑎2 𝑘2
2

𝑘2 +(𝑥−𝑥2 )2

In Eq 4.2, a1, a2, k1, k2, x1, and x2 are the fitting variables optimized with least squares to
produce a Lorentzian function for imaging data. The CEST data for liposomes before and after
air exposure were modeled with Mathematica commands in Figure 4.5. These commands
included a calculation and plot of relative error per data point, which was plotted with the fitted
function for blank liposomes (Figure 4.6).

Figure 4.5. Mathematica commands or Lorentzian curve fitting CEST imaging data and relative
error per data point for blank liposomes.
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Figure 4.6. Mathematica output for blank liposomes of (a) fitted variables, (b) Lorentzian
function plotted with raw CEST data, and (c) relative error calculated for each data point.
The Lorentzian function reported in the results and discussion section was generated
using the fitted variables defined in Eq 4.2, but plotted in the form of Eq 4.3.
Eq 4.3

𝑦 =1−(

𝑎1 𝑘1
2

𝑘1 +(𝑥−𝑥1

)2

+

𝑎2 𝑘2
2

𝑘2 +(𝑥−𝑥2 )2

)
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4.2.8 Dynamic Light Scattering Data

Figure 4.7. Intensity percent vs size of liposomes containing 45 mM 1.33 used for in vitro CEST
imaging prior to air exposure.

Figure 4.8. Intensity percent vs size of liposomes that contained 45 mM 1.33 used for in vitro
CEST imaging after 24 h of air exposure.

Figure 4.9. Intensity percent vs size of liposomes containing 45 mM 1.33 used for in vitro T1weighted imaging prior to air exposure.
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Figure 4.10. Intensity percent vs size of liposomes that contained 45 mM 1.33 used for in vitro
T1-weighted imaging after 24 h of air exposure.
4.3 Results and Discussion
Liposomes were used because their aqueous inner cavity can encapsulate water-soluble
contrast agents to improve the sensitivity of CEST by increasing the ratio of chemically shifted
water protons (associated with liposomes) to bulk water protons (not associated with
liposomes).168,169 Liposome composition was adapted from a report that used 1-palmitoyl-2oleoyl-sn-glycero-3-phosphocholine and cholesterol,51 and liposomes were characterized using
dynamic light scattering. The average diameter measured before and after air exposure was 110
± 7 and 106 ± 6 nm, respectively, where the diameter error is the standard error calculated from
the average polydispersity index values. The average liposome polydispersity index value before
and after air exposure was 0.14 ± 0.01 and 0.10 ± 0.06, respectively, where the polydispersity
index error is the standard error at the 95% confidence interval. These size distribution data
indicate that average liposome size was not different before and after oxidation (Student’s t-test)
and, consequently, not affected by the intraliposomal formation of EuIII.
To evaluate the response of the liposomes, 45 mM 1.33 was encapsulated because of
previous studies that loaded similar or higher concentrations of paramagnetic complexes into
liposomes.61,168,169 After removing non-encapsulated 1.33 by spin filtering, suspensions of
liposomes containing 1.33 were characterized before and after exposure to air. Molecular oxygen
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within air was chosen as a convenient source of oxidant to demonstrate a response corresponding
to oxidation of 1.33. This mechanism of response is most likely diffusion of oxygen into the
buffer and across the liposome membrane. Once oxygen has crossed the membrane, it can
oxidize 1.33 (T1 enhancing agent) to form 4.1 (T1 silent), and consequently, the response to
oxidation can be detected by loss of T1 enhancement. Support for the oxygen diffusion
mechanism was found by measuring the change in T1 as a function of air exposure for liposome
suspensions containing 1.33. Without stirring, 1.33 within liposomes required 7 h to oxidize in
air. Upon stirring, however, 1.33 within liposomes oxidized within 10min of air exposure.
Stirring the solution would facilitate an increased rate of oxygen diffusion, which would
accelerate the rate of oxidation. To ensure complete oxidation of 1.33 to form 4.1 within the
oxidized samples, liposomes were exposed to air for 24 h without stirring because of the small
size of the sample tube prior to imaging. After air exposure an 86% decrease in T1 (0.4 and 2.8 s
for the same sample before and after air exposure, respectively, at 24 °C, 11.7 T, and 45 mM in
Eu) was observed, which is a response similar to or greater than other reported contrast
agents.33,67,88,170–176 A rationale for the large change in T1 is that EuII is isoelectronic with GdIII,
but EuIII is diamagnetic in its ground state and is not expected to dramatically influence T1. The
observation of T1 changing upon air exposure is in good agreement with the T1-shortening nature
of 1.33 (relaxivity was 3.99 mM–1 s–1 outside of liposomes and 0.2 mM–1 s–1 inside of liposomes
at 20 °C and 11.7 T. The lower relaxivity is expected for T1-shortening contrast agents
encapsulated in spherical liposomes).97,98,177 Furthermore, the change in T1 upon air exposure
indicates that oxidation to form 4.1 caused the observed lengthening of T1.
To characterize the dual-mode behavior of Eu-containing liposomes, CEST response
before and after air exposure by measuring in vitro image intensities as a function of frequency
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offset of presaturation at 7 T was measured (Figure 4.11). The intensity data was modeled with a
Lorentzian function using least squares fitting to reference the upfield signal to 0 ppm (Figure
4.12). Lorentzian fitting was use because the sample images were acquired simultaneously and
the bulk water signals were not centered at 0 ppm. Averaging the CEST spectra was performed
because it appeared that both the proximity to the bulk water signal and inhomogeneity in the
magnetic field led to variability in the intensity measurements. The average CEST spectra
(Figure 2) revealed that liposomes before and after 24 h air exposure exhibited an exchangeable
proton signal at 1.2 ppm relative to bulk water. Although this shift is small, it is possible to
image such shifts in vivo:77,178–182 in vivo CEST has been observed between bulk water and
exchangeable protons of liposomes shifted by as little as 0.8 ppm.77
To investigate the cause of CEST effect before oxidation of Eu, CEST spectra were
acquired for a series of samples including blank liposomes containing only phosphate-buffered
saline, liposomes containing 4.2 (28 mM Sr) as a diamagnetic analogue, and liposomes
containing four different concentrations of 1.33 (13, 24, 40, and 45 mM Eu). CEST effect was
observed for each sample as a broad signal in the chemical shift range of 1–2 ppm relative to
bulk water. Furthermore, there was no correlation between Eu concentration and CEST effect.
These experiments suggest that the observed CEST effect is due to the liposome membrane itself
rather than Eu within the liposome cavity. These results are fully consistent with a recent
demonstration of a CEST effect using diamagnetic liposomes that contained cholesterol and, of
particular importance, the proton signal at ~1 ppm downfield from bulk water was assigned to
hydroxyl protons.77 Additional support for these observations can be found in a previous report
of magnetization transfer for a lipid and cholesterol system in which magnetization transfer
exhibited a strong dependence on cholesterol concentration (30–60 mol %),183 and the
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concentration of cholesterol in the system reported here (42 mol %) falls in this range.
Furthermore, these data provide an explanation for the observation of CEST before oxidation of
EuII by revealing an exchange between the liposome membrane and bulk water. In this proposed
exchange mechanism, 1.33 is confined to the intraliposomal cavity and, consequently, would not
interact with protons exchanging on the outer surface of the liposome.

Figure 4.11. CEST spectra (7 T, ambient temperature) of 1.33-containing liposomes before ()
and after () 24 h air exposure. Data points represent the mean of six independently prepared
samples [liposomes containing only phosphate-buffered saline; 4.2 (28 mM Sr); and 1.33 (13,
24, 40, and 45 mM Eu)], and error bars represent the standard error of the mean. The upfield
signal was referenced to 0 ppm using the Lorentzian-fitted spectra and signal intensities were
calculated from in vitro images after a 2 s presaturation with a 17 µT radiofrequency pulse from
5 to –5 ppm in 0.2 ppm increments.
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Figure 4.12. Lorentzian-fitted CEST spectrum (7 T, ambient temperature) of liposomes filled
with phosphate-buffered saline. The upfield signal was referenced to 0 ppm, and signal
intensities were calculated from in vitro images after a 2 s presaturation with a 17 µT
radiofrequency pulse from 5 to –5 ppm in 0.2 ppm increments.
To visualize the nature of the EuII/III responses, in vitro images of liposome suspensions
were acquired before and after air exposure (Figure 4.13). The T1-weighted images confirmed
positive contrast enhancement for the 1.33-containing liposomes and also revealed no significant
difference in signal intensity between water and the oxidized EuIII-containing liposomes at the
95% confidence interval (Student’s t-test). Additionally, there was an 81% decrease in signal
intensity in T1-weighted images before and after oxidation. To quantify the CEST effect, the
phantom image intensities were used to calculate %CEST defined as (1 – Mz/M0)100, where Mz
and M0 are the average signal intensities at the on- and off-resonance positions.167 The CEST
map confirmed the presence of exchangeable protons before and after oxidation and that %CEST
was not significantly different after oxidation based on the standard error of the CEST effect
measurements in Figure 4.11. Based on control experiments, the change in CEST effect is not
due to the presence of Eu, despite the influence of T1 on the CEST effect.184 Nevertheless, these
data demonstrate a distinct dual-mode response and reveal the oxidation state of Eu without
knowledge of its concentration. Therefore, (1) if T1 enhancement and CEST effect are both
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present, the agent has not responded. Similarly, (2) if T1 enhancement is no longer observed and
CEST effect is still present, then the agent has responded. If neither forms of contrast are
detected, then (3) the agent is no longer present or is present at a level below the detection limit
of MRI. Based on these three scenarios, one can determine the oxidation state of Eu (and
therefore a response) without knowledge of the concentration of Eu. This method does not
quantify the amount of oxidant present, but reports on the oxidation itself in a concentrationindependent manner by using two orthogonal detection modes (one of which changes and one of
which does not change in response to oxidation).
With this demonstration of distinct orthogonal imaging, tracking the migration of the
contrast agent could be achieved with T1-weighted imaging. Upon disappearance of T1
enhancement, the imaging mode of detection would be changed to CEST. The presence of CEST
effect would indicate oxidation, and an absence of CEST effect would indicate clearance of the
contrast agent. Furthermore, CEST effect could be used to indicate one or more specific disease
states because the oxidation potential, and consequently loss of T1 enhancement, of 1.33 is
tunable through ligand structure modifications.101 Accordingly, these in vitro data provide a
strong framework for optimizing this system for in vivo imaging.
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Figure 4.13. MR phantom images (5 mm tube diameter) at 7 T and ambient temperature of
water, non-oxidized liposomes containing EuII, and oxidized liposomes containing EuIII. In the
top row are T1-weighted images and on the bottom is a CEST map generated by subtracting
presaturation at 1.2 ppm from presaturation at –1.2 ppm and the difference was divided by
presaturation at –1.2 ppm. %CEST represents the decrease in bulk water signal intensity as a
result of presaturation exchangeable water protons associated with liposomes.
The kinetic stability of 4.1 relative to 1.33 is of importance because of the toxic nature of
uncomplexed trivalent lanthanide ions. It has been demonstrated that 4.1 is less kinetically stable
relative to 1.33,103 which is primarily due to the reduction in size of Eu upon oxidation. To
demonstrate that liposomes did not leach Eu, the oxidized liposomes were filtered, and the Eu
concentration of the filtrate was measured to be below the detection limit (<66 nM) of
inductively coupled plasma optical emission spectroscopy. This result indicates that the liposome
traps uncomplexed EuIII, which is likely present as a species coordinated with phosphate from
the buffer, phosphate from the phospholipid membrane, or as the free aqua ion.
4.4 Conclusions
The first oxidation-responsive dual-mode contrast agent for MRI based on the redox
chemistry of Eu was demonstrated. Contrast enhancement in orthogonal imaging modes allows
for the detection of Eu oxidation states without knowledge of contrast agent concentration.
Notably, the response of this system is irreversible due to the stability of EuIII with respect to
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reduction. Irreversible response is potentially advantageous in vivo because the contrast agent is
in a dynamic environment and can indicate oxidation even if no longer in the oxidizing region.
For these reasons, this system is expected to open the door for molecular imaging using the
EuII/III redox switch, and the scope of the system is being explored to identify physiologically
relevant oxidants and the kinetics of intraliposomal EuII oxidation.
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CHAPTER 5: SPECTROSCOPIC CHARACTERIZATION OF THE 3+ AND 2+
OXIDATION STATES OF EUROPIUM IN A MACROCYCLIC TETRAGLYCINATE
COMPLEX
Parts of this chapter have been adapted with permission from Ekanger, L. A.; Mills, D. R.; Ali,
M. M.; Polin, L. A.; Shen, Y.; Haacke, E. M.; Allen, M. J. Inorg. Chem. [Online early access].
DOI 10.1021/acs.inorgchem.6b00629. Published online May 31, 2016. Copyright 2016
American Chemical Society.
5.1 Introduction
The majority of lanthanide chemistry occurs in the 3+ oxidation state, where the relative
stability of this valency makes metal-based redox chemistry somewhat uncommon. However,
there is growing interest in the formation, characterization, stabilization, and application of
complexes containing lanthanides outside of the 3+ oxidation state.73,125,131,185–194 For example, it
was only in 2013 that the full series of divalent lanthanides was reported.187 The 2+ oxidation
state for all lanthanides is air sensitive, but the half-filled 4f7 electronic configuration of EuII
makes it the most stable divalent lanthanide with respect to oxidation. This stability permits the
study of EuII-containing complexes in aqueous media. The study of aqueous EuII-containing
complexes is important because they are redox-active complexes relevant to responsive magnetic
resonance imaging (MRI).73,125,194
MRI permits non-invasive imaging at high spatial resolution and nearly unlimited depth
penetration.21,140 Images acquired using MRI can be enhanced through the use of paramagnetic
complexes (contrast agents) that influence the properties of the nuclei being imaged, which are
often the protons on water molecules. In addition to highlighting spatial information using
paramagnetic complexes, contrast agents have been designed to relay molecular information via
changes in ligand structure or metal oxidation state.33,40,66,69,71–73,125,194–196 However, the majority
of responsive contrast agents are limited by concentration-dependent responses that make
distinguishing pre- and post-response states difficult in vivo.124 A promising platform for
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concentration-independent responsive imaging is the EuIII/II redox couple. EuII is analogous to the
commonly used GdIII ion in providing longitudinal-relaxation-time (T1)-shortening (positive)
contrast enhancement.73,97–99,102,125–129 However, unlike GdIII, EuII is redox active under
physiologically relevant conditions. The EuII ion can undergo a one-electron oxidation to the 3+
oxidation state that does not noticeably influence positive contrast enhancement,8,9 and the first
use of EuII-containing complexes as redox-active contrast agents were reported in vivo.9,10
In chapter 3, complex 3.6 persisted in the 2+ oxidation state in necrotic (oxygendeficient) tumor tissue of a mammary carcinoma after an intratumoral injection.9 The persistence
of EuII within the necrotic tissue allowed the visualization of necrotic tissue using positive
contrast enhancement. These data suggested that EuII was oxidized and cleared from nonnecrotic tissue that permitted differentiation of necrotic tissue by 120 min post injection.
However, the products of oxidation were not detectable by MRI in these studies, which
motivated the synthesis and characterization of a complex detectable in both the 3+ and 2+
oxidation states of Eu. To enable visualization of the Eu-based contrast agent after oxidation,
EuII was combined with a ligand used for chemical exchange saturation transfer (CEST) contrast
in MRI. In this chapter, spectroscopic characterization of a EuIII/II tetraglycinate complex is
reported demonstrating the conversion from the 3+ to 2+ and 2+ to 3+ oxidation states.
Furthermore, selective suppression of T1 or CEST contrast based on the oxidation state of Eu was
demonstrated.
One-electron reduction of a EuIII-containing MRI contrast agent was hypothesized to
produce a EuII-containing complex that provides positive contrast enhancement in T1-weighted
MRI, but could be oxidized to the original complex that provides CEST contrast in MRI.
Demonstrating conversion between oxidation state changes is necessary for a thorough
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understanding of the solution-phase behavior of each oxidation state. Accordingly,
luminescence, electron paramagnetic resonance (EPR), nuclear magnetic resonance (NMR), and
UV–visible spectroscopies were selected to characterize both oxidation states in solution.
Because the potential applications of these complexes are in aqueous solution, the focus was
solution characterization for this study. Accordingly, gas- or solid-phase analyses were not
performed as they do not convey the stability or solution-phase properties of complexes.
EuIII-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(acetamidoacetate)

(5.1)

was

chosen because it contains chelated EuIII, is commercially available, and is among the tetraamide
group of contrast agents that are well-characterized with respect to CEST imaging.45,68,70,84,85,196–
200

CEST imaging is an MRI technique that produces contrast via selective radiofrequency

presaturation of exchangeable protons. During the saturation event, saturated protons on the
contrast agent exchange with non-saturated water protons (commonly referred to as bulk water
protons). The saturation event results in a decrease in the bulk water proton signal intensity, and
this decrease is used to produce contrast in the resulting images. The ability to detect CEST
contrast is affected by the difference in bound- and bulk-water proton resonance frequencies that
are often expressed as chemical shifts (units of ppm). Under certain circumstances, relatively
small diamagnetic chemical shift differences (<3 ppm) can be imaged in vivo;77 however,
magnetization transfer effects between lipids and other macromolecules broaden the bulk water
signal in vivo, making contrast agents with relatively large chemical shift offsets desirable.
Complex 5.1 paramagnetically shifts bound-water protons downfield from bulk water by
55 ppm, and similar shifts have been imaged in vivo.68 Upon reduction of 5.1 to 5.2, the EuII ion
was expected to relax the nuclear dipole moments of nearby protons resulting in the complete
quenching of saturation transfer effects. Instead of CEST contrast, 5.2 was expected to enhance
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contrast in T1-weighted MRI in accordance with previously reported EuII-based complexes:73,97–
99,102,125–129,194

5.2 would provide positive contrast enhancement until it was oxidized to 5.1, at

which point it would display CEST contrast (Figure 5.1). Here, luminescence, electron
paramagnetic resonance (EPR), NMR, and UV–visible spectroscopic data characterizing the
conversion from the 3+ to 2+ and 2+ to 3+ oxidation states of EuIII/II-DOTA-4AmC are reported.

Figure 5.1. Reduction of a commercially available CEST contrast agent (5.1) to the T1shortening EuII-containing analogue (5.2) using Zn0 under an atmosphere of N2. Oxidation to the
3+ oxidation state yields the original complex. The table compares magnetic and spectroscopic
properties between EuIII- and EuII-containing complexes in the ground state.
5.2 Experimental Procedures
Commercially available chemicals were of reagent-grade purity or better and were used
without further purification unless otherwise noted. Phosphate-buffered saline (PBS, 10×) was
purchased from Fisher BioReagents. 5.1 was purchased from Macrocyclics. Water was purified
using a PURELAB Ultra Mk2 water purification system (ELGA) and degassed under reduced
pressure prior to use.
DOWEX 50Wx8 sulfonic acid resin was converted to the sodium form (DOWEX-Na+)
by swirling the resin (3 g) in aqueous NaOH (1 M, 10 mL) for 5 min before allowing the resin to
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settle and decanting the supernatant. Excess NaOH was removed by washing the resin with water
(10 × 10 mL) until the pH of the washings was 7. Residual solvent was removed from the resin
under reduced pressure before the resin was brought into a wet glovebox with an atmosphere of
N2 at which point it was swelled with degassed water.
5.2.1 Cyclic Voltammetry. Cyclic voltammetry was performed using a three electrode
setup composed of a glassy carbon working electrode, a platinum wire auxiliary electrode, and a
Ag/AgCl reference electrode coupled with a Pine Wavenow USB or BAS 50W potentiostats.
Acquisition parameters for the cyclic voltammogram of EuII/III-DOTA-4AmC (Figure 5.4A)
were 8 segments, initial potential of –1.4 V (rising), upper potential of 0 V, lower potential of –
1.4 V, final potential of –1.4 V, and a sweep rate of 150 mV/s. Acquisition parameters for the
cyclic voltammogram of EuII/III-DOTA-4AmC (Figure 5.4B) were 8 segments, initial potential
of 0.5 V (falling), lower potential of –1.4 V, upper potential of 0.5 V, final potential of 0.5 V,
and a sweep rate of 100 mV/s. Samples were prepared by dissolving 5.1 and
tetraethylammonium perchlorate or potassium chloride in water. The pH of the resulting solution
was 4 and was adjusted to 7 using aqueous NaOH (1 M) for the potassium chloride solution. The
solutions were sparged with Ar while stirring for 5 min prior to measurements, but were not
sparged or stirred during the measurements. The standard potential is reported as mean ±
standard error of 3 independently prepared samples.
5.2.2 Reduction of 5.1 with Zn0. 5.2 was prepared by vigorously stirring 5.1 (4.0 mg, 4.2
µmol, 1 equiv) with Zn dust (50.0 mg, 760 µmol, 181 mol equiv, 362 electron equiv) in water
(0.700 mL) for 1 min to produce a yellow supernatant. Excess Zn dust was removed by filtering
the mixture through a 0.2 µm hydrophilic filter. The yellow filtrate was mixed with DOWEXNa+ (0.1 g) for 1 min before resin was removed by filtering through a 0.2 µm hydrophilic filter,

99

and this process was repeated twice more. This cation-exchange step reduced the concentration
of ZnII to below the detection limit (<1 ppb) of inductively coupled plasma mass spectrometry
(ICP–MS). To the remaining yellow filtrate was added 10× PBS and water to bring the final
concentration to 4 mM Eu in 1× PBS (pH = 7.4 ± 0.2). Subsequent dilutions were performed
with degassed 1× PBS under an atmosphere of N2.
5.2.3 Elemental concentration measurements. The concentrations of Eu and Zn were
determined using ICP–MS or energy dispersive X-ray fluorescence (EDXF) spectroscopy. ICP–
MS measurements were acquired on an Agilent Technologies 7700 series ICP–MS instrument at
the Lumigen Instrument Center in the Department of Chemistry at Wayne State University. All
dilutions were performed with aqueous 2% HNO3, which was also used for blank samples during
calibration. Calibration curves were created using the
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Eu isotope ion count for a 1–200 ppb

concentration range (diluted from Fluka ICP standard solution, 1000 mg Eu/L) or the
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Zn

isotope ion count for a 1–200 ppb concentration range (diluted from Fluka ICP standard solution,
1000 mg Zn/L). EDXF measurements were performed with a Shimadzu EDX-7000 spectrometer
(Shimadzu Scientific Instruments). Calibration curves were created using the Eu fluorescence
intensity at 5.845 keV for a 250–1000 ppm concentration range (diluted from Fluka ICP standard
solution, 1000 mg Eu/L).
5.2.4 Luminescence spectroscopy. Emission spectra were acquired on a HORIBA Jobin
Yvon FluoroMax-4 spectrofluorometer and samples were loaded into quartz cuvettes and sealed
with air-tight caps under an atmosphere of N2. An emission range of 550–725 nm was recorded
with excitation at 395 nm (1 nm slit widths and 1 nm resolution).
5.2.5 Minimum detectable concentration of 5.1. The minimum detectable
concentration of 5.1 was determined by a textbook procedure.201 The absolute emission intensity
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at 595 nm was measured after excitation at 395 nm (1 nm slit widths and 1 nm resolution) as a
function of concentration of 5.1 (Figure 5.2). The emission intensity of 5.1 (0.0662 mM) was
measured using 7 independently prepared samples, and the standard deviation of the emission
intensities was 2200 units. Using Eq 5.1,201 where σ and m [(3.15 ± 0.01) × 105 units mM–1] are
the standard deviation and slope of emission intensity vs concentration, respectively, the
minimum detectable concentration of 5.1 was 20.9 µM.

Figure 5.2. Absolute intensity vs concentration of 5.1. The lowest point was measured 7 times
using independently prepared samples to determine the minimum detectable concentration as
described in the experimental section of this chapter.
Eq 5.1

𝑚𝑖𝑛𝑖𝑚𝑢𝑚 𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑏𝑙𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =

3𝜎
𝑚

5.2.6 EPR spectroscopy. EPR spectroscopy was performed on a Bruker EMX X-band
spectrometer equipped with an Oxford variable-temperature cryostat. EPR samples were
prepared and sealed with wax under an atmosphere of N2 and were a total volume of 0.3 mL in
Norell SEPR250S EPR tubes. Aqueous solutions in EPR tubes were frozen in liquid nitrogen
prior to loading into the sample cavity. EPR spectra were acquired of 5.1 and 5.2 in water.
Acquisition parameters included a temperature of 110 K, microwave frequency of 9.378654
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GHz, microwave power of 1.992 mW, modulation frequency of 100 kHz, receiver gain of 30 dB,
and modulation amplitude of 4.0 G.
5.2.7 1H-NMR spectroscopy. NMR spectra were acquired on a Varian VNMRS-500
(499.48 MHz, 11.7 T) in the Lumigen Instrument Center in the Chemistry Department at Wayne
State University.
5.2.8 UV–visible spectroscopy and dissociation kinetics. UV–visible spectra were
acquired on a Shimadzu UVmini-1240 spectrophotometer and samples were loaded into quartz
cuvettes and sealed with air-tight caps under an atmosphere of N2. Extinction coefficients were
calculated by dividing the absorbance maxima by the concentration of Eu in the sample for a 1
cm path length.
The dissociation rate of 5.2 was calculated by monitoring absorbance at 425 nm as a
function of time in 0.1 M HCl. This method was chosen based on reports that characterize the
kinetic stability of similar complexes.202 The absorbance at 425 nm was chosen because it is
within an absorbance range specific to the EuII-containing complex (415–485 nm), whereas the
EuII aqua ion (a product of dissociation) does not absorb beyond 415 nm. The UV–visible spectra
of 5.2 in the 415–485 nm range revealed a decrease in the concentration of 5.2 as a function of
time. The concomitant formation of the EuII aqua ion absorbance profile ruled out the possibility
of oxidation being responsible for the loss of 5.2 in this experiment. The absorbance values at
425 nm as a function of time were used to calculate the dissociation rate based on Eq 5.2,198
where kd is the calculated first-order dissociation rate constant; t is time; and A0, At, and Ae are
the absorbance values measured at the start of the reaction (t = 0 s), at time t, and at a final time
of t = 5400 s, respectively.
Eq 5.2

𝑘𝑑 =

1

𝐴 −𝐴

𝑙𝑛 ( 𝐴0 − 𝐴 𝑒)
𝑡
𝑡

𝑒
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5.2.9 CEST measurements. CEST spectra were acquired on the same spectrometer used
to acquire 1H-NMR spectra with a sample temperature of 22 °C using a saturation frequency
array with saturation time of 4 s, a saturation power of 24 µT, a 45 degree observe pulse, an
initial frequency of 100 ppm (50,000 Hz), and a final frequency of –100 ppm (–50,000 Hz) in 1
ppm (500 Hz) increments. All samples were in 1× PBS (pH = 7.4 ± 0.2) and included 5.1, 5.2,
and 5.1 after oxidation of 5.2 by exposure to air. The concentration of Eu in all samples was 4
mM.
5.2.10 Relaxivity measurements. T1 measurements were performed on a Bruker
Minispec mq60 NMR (1.4 T) spectrometer at 37 °C by measuring T1 with inversion recovery
experiments. Relaxivity was obtained from the slope of 1/T1 vs concentration of either 5.1 or 5.2
using a linear regression fitting (Figure 5.3). All samples were measured in 1× PBS (pH = 7.4 ±
0.2). Measurements were performed in triplicate with independently prepared solutions, and the
relaxivity values are reported as the mean ± standard error of the mean of the independent
measurements.
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Figure 5.3. Longitudinal relaxation rate (1/T1) vs concentration of independently prepared
solutions of 5.2 (top row) or 5.1 (bottom row).
5.2.11 Magnetic resonance imaging. Details for the mouse imaging experiments have
been described in chapter 3.125 Magnetic resonance imaging was performed with a Varian small
animal scanner (299.44 MHz, 7.0 T) at Henry Ford Hospital equipped with a 12 cm bore magnet
and a 38 mm diameter homemade transmit–receive quadrature birdcage coil. All samples, with
the exception of water, were in 1× PBS (pH = 7.4 ± 0.2) and included 5.1, 5.2, and 5.1 after
oxidation of 5.2 by exposure air. The concentration of Eu in all samples was 4 mM, with the
exception of water that was 0 mM. The T1-weighted images were acquired at ambient
temperature with an echo time of 15.68 ms, repetition time of 800 ms, 13 slices at 1 mm
thickness, 24 mm × 24 mm field of view, and 4 averages. CEST images were acquired of the
exact same samples in the same instrument using a magnetization transfer pulse sequence with a
7 µs (500°) saturation pulse at 55 ppm (16,500 Hz) and –55 ppm (–16,500 Hz).
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5.3 Results and Discussion
5.3.1 Monitoring EuIII/II oxidation state changes and reversibility. To characterize the
electrochemical potential of 5.1, cyclic voltammetry (Figure 5.4) was performed and a reversible
one-electron redox couple with an E1/2 of –0.879 ± 0.001 V vs Ag/AgCl (Epa – Epc = 57 mV) was
observed. This value is inconsistent with a report published during the preparation of this
chapter.203 The other report claimed the reduction potential of 5.2 to be more positive than the
reduction potential of the EuII aqua ion. The observation in the other report is unexpected based
on the presence of four amide functional groups that are known to exhibit delocalization of
negative charge onto the amide carbonyl oxygens through resonance, but the cyclic
voltammograms in that manuscript did not scan to a negative enough potential to observe the
same E1/2 observed in Figure 5.4. To match the conditions of the other report, a separate cyclic
voltammogram was acquired using potassium chloride as the supporting electrolyte at pH 7.
Under these conditions, an E1/2 of –0.903 V vs Ag/AgCl was measured. The similar E1/2 values at
pH 4 and 7 are not surprising given that the electron transfer is not proton coupled. Without
sparging the solution with Ar, a similar signal to that in the other report was observed;203
however, this signal was no longer observed after sparging with Ar. Furthermore, the measured
potentials

are

consistent

with

electrochemical

studies

of

EuIII/II-based

complexes.101,102,126,128,132,133 In those reports, there is a correlation between increasing numbers
of anionic donor functional groups, such as carboxylates, and increasingly more negative
reduction potentials. This trend is consistent with what would be expected for electron-rich metal
ions like EuII.
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Figure 5.4. Cyclic voltammograms of (A) EuII/III-DOTA-4AmC (3 mM) with
tetraethylammonium perchlorate (50 mM) as the supporting electrolyte (pH = 4) and (B) EuII/IIIDOTA-4AmC (10 mM) with potassium chloride (100 mM) as the supporting electrolyte (pH =
7).
In addition to having an E1/2 that is reasonable for a tetraamide complex of EuIII/II, the
reversible nature of the cyclic voltammograms in this report are consistent with a complex
exhibiting reversible electron transfer characteristics. This observation is of fundamental
importance when studying cyclen-based ligands that contain carboxylate groups because of the
potential for incomplete chelation with these types of complexes. This phenomenon is welldocumented with trivalent lanthanide ions and ligands bearing acetate functional groups on
cyclen rings.204 The rate of chelation is determined, in part, by the protonation state of the
ligand.204 While the addition of hydroxide accelerates the rate of chelation, the rate decreases
with decreasing charge density, which is inversely proportional to ionic radius, of the lanthanide
being used.204 EuII is larger (ionic radius of ~117 pm) than the largest trivalent lanthanide ion,
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LaIII (ionic radius of ~103 pm),205 and EuII also has a lower charge than LaIII. The relatively large
radius and low charge would be expected to cause EuII to form a complex with cyclen-based
ligands much more slowly than any trivalent lanthanide ion. Therefore, it appears that starting
from a EuIII-containing precursor is beneficial when studying the electron transfer chemistry of
poly(amino carboxylate) or poly(amino glycinate) complexes.
Based on the E1/2 of EuIII/II-DOTA-4AmC, Zn0 (E1/2 = –0.960 V vs Ag/AgCl)206 was
expected to be a suitable reductant for the EuIII ion in this complex. Upon stirring aqueous 5.1 in
the presence of Zn0 under an atmosphere of N2, a rapid (<1 min) formation of a yellow color
from the previously colorless solution was observed.
To probe for the presence of EuIII in the yellow solution, luminescence spectroscopy was
performed. The emission spectrum of 5.1 contained the characteristic emission bands from the
radiative decay of the 5D0 excited state of EuIII to the 7F manifold (Figure 5.5), and the yellow
solution did not produce observable EuIII-based emissions despite having the same concentration
of Eu. To quantify the loss of EuIII, the minimum detectable concentration of EuIII using the
emission of 5.1 at 595 nm was measured. The minimum detectable concentration of 5.1 was 20.9
µM, indicating that the reduction reaction removed ≥99.0% of the initial EuIII. However,
bubbling air into the yellow solution resulted in a colorless solution that produced an emission
spectrum identical to 5.1 in both emission wavelength and absolute intensity. These data suggest
that the reaction with Zn0 was responsible for the absence of EuIII-based emissions in the yellow
solution, and that the species responsible for the yellow color reacts with air to reform 5.1.
Additionally, the complete recovery of the

5

D0 to

7

F2 emission at 615 nm, which is

hypersensitive to coordination environment, strongly suggests that the EuIII coordination
environment of the 5.1 starting material and the complex formed after oxidation of the reduced
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species are the same. Although luminescence experiments offered evidence for the absence and
quantitative recovery of EuIII, EPR spectroscopy was used to detect the presence of EuII.
To verify the formation of EuII, EPR spectra of 5.1 and the yellow solution at equal
concentrations of Eu were acquired. The EPR spectrum of aqueous 5.1 was consistent with that
of a diamagnetic sample (Figure 5.5). The diamagnetic behavior of EuIII is expected because of
its 4f6 ground state electronic configuration where the total angular momentum quantum number
is 0, causing the effective magnetic moment to be 0 Bohr magnetons despite the presence of 6
unpaired electrons. The reason EuIII exhibits paramagnetic behavior at non-cryogenic
temperatures is because excited states with nonzero effective magnetic moments are thermally
accessible. The EPR spectrum of the yellow solution contained a broad resonance (g-factor =
1.99) consistent with the presence of EuII.129 Additionally, a lack of precipitation upon the
addition of phosphate indicates that the EuII species remains chelated in solution. The
luminescence and EPR data combined with the lack of a precipitate in the presence of phosphate
indicate that the yellow solution contained 5.2.
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Figure 5.5. (A) Emission spectra (395 nm excitation) of 5.1 (– –), 5.2 (—), and 5.1 after
oxidation of 5.2 by exposure to air (··). The dashed and dotted lines overlap exactly. All solutions
were 2 mM in degassed water under an atmosphere of N2 for EuII or air for the oxidized sample.
(B) EPR spectra of 5.1 (– –) and 5.2 (—) in H2O at 110 K under an atmosphere of N2.
The chelation of EuII within DOTA-4AmC was further interrogated by acquiring 1HNMR spectra of 5.1, 5.2, and 5.1 after oxidation of 5.2 by exposure to air (Figure 5.6). To better
the chances of observing free ligand in the NMR experiment, the concentration of the complex
was increased by roughly an order of magnitude relative to all of the other experiments (from 2
to 23 mM). Signals for the EuIII-containing samples were observed and are consistent with the
chemical shifts of a previously reported ester analogue of 5.1.197 In the reduced sample, broad
peaks were observed in the range of 0 to 5 ppm that were assigned to the EuII-containing
complex, as would be expected for protons of ligands bound to the isotropic EuII ion. Isotropic
ions, such as EuII and GdIII, are known to shorten relaxation times of nearby nuclei leading to a
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broadening effect. Anisotropic ions, such as EuIII and TbIII, shift the resonance of nearby nuclei
without the degree of line broadening observed with isotropic ions. The absence of free ligand 198
in the 5.1 spectrum after oxidation of the reduced sample provides further evidence that no
detectable dissociation occurred during the reduction or oxidation. This study corroborated the
absence of 5.2 dissociation indicated by cyclic voltammetry, emission spectroscopy, and
phosphate solubility observations. The apparent lack of dissociation upon producing 5.2
motivated the measurement of dissociation kinetics, and the yellow color suggested that UV–
visible spectroscopy could be used to monitor dissociation rates.

Figure 5.6. 1H-NMR spectra of 5.1 (top), 5.2 (middle), and 5.1 after oxidation of 5.2 by
exposure to air (bottom). All solutions contained 23 mM of complex in degassed D2O under an
atmosphere of N2 for EuII or air for the oxidized sample.
5.3.2 Conditional kinetic stability of 5.2 in acid. The kinetic stability of a Lncontaining contrast agent is a critical piece of characterization because low kinetic stability can
lead to undesired dissociation of the metal ion from the complex. The dissociation rate of 5.1 (8.1
× 10–6 s–1 corresponding to a dissociation half-life of 237 h) has been reported at pH 1;202
therefore, the UV–visible spectrum of 5.1 and 5.2 (Figure 5.7) were acquired at pH 1 to enable
comparisons between the kinetic stabilities of these two complexes. It should be noted that acidcatalyzed dissociation kinetics are not representative of kinetic stability under physiological
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conditions, but these kinetics are of use when comparing complexes whose dissociation was
measured under the same conditions. The UV–visible spectrum of 5.1 contained a small chargetransfer band centered at 250 nm (extinction coefficient of 5.16 × 102 M–1 cm–1) that has been
reported for this complex.198 However, the UV–visible spectrum of the 5.2 at pH 1 at the initial
time point contained two broad absorptions centered at 250 and 353 nm (extinction coefficients
of 1.77 × 103 and 9.36 × 102 M–1 cm–1, respectively). These absorptions are consistent with EuIIbased transitions.207 A 33 nm bathochromic shift of the longer wavelength absorption maximum
of 5.2 relative to EuCl2(aq) (353 vs 320 nm, respectively) caused the absorption profile of 5.2 to
extend to 485 nm (imparting a yellow color to the solution), while the absorption of EuCl2 only
extended to 415 nm. Therefore, to measure the kinetic stability of 5.2, absorption at 425 nm was
measured as a function of time (Figure 5.7).
The dissociation rate of 5.2 was 9.2(5) × 10–4 s–1, which corresponds to a dissociation
half-life of 13 min. This dissociation rate of 5.2 is ~110× faster than the dissociation rate of 5.1.
A faster dissociation is not surprising upon reduction of EuIII to EuII: The EuII ion is a relatively
soft Lewis acid compared to EuIII; consequently, a relatively weaker binding interaction is
expected between the oxygen atoms of the amide functional groups and Eu II compared to EuIII.
However, despite a decrease in kinetic stability, the dissociation rate of 5.2 is between the
dissociation rates of two clinically approved contrast agents, 2.1 and 3.7, that have dissociation
rates of 1.2 × 10–3 and 2.1 × 10–5 s–1, respectively.202 These data suggest that the kinetic stability
of 5.2 is not a hindrance for in vitro solution-phase characterization or preclinical in vivo
imaging, but further investigation is warranted.
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Figure 5.7. (A) UV–visible absorption spectra of 5.1 (– –), 5.2 at t = 0 s (—) and t = 5400 s (— ·
—), and EuCl2 (— · · —). All samples were measured in 0.1 M HCl. (B) 5.2 absorption at 425
nm as a function of time in 0.1 M HCl. Error bars represent the standard error of the mean of
three independent measurements.
5.3.3 In vitro CEST and T1 measurements of EuIII/II-DOTA-4AmC. To evaluate the
effect of the 2+ oxidation state of Eu on CEST, CEST spectra of 5.1, 5.2, and 5.1 produced from
the oxidation of 5.2 (Figure 5.8) were acquired. The CEST spectrum of 5.1 matched the reported
CEST spectrum with a signal 55 ppm downfield from bulk water.208 Upon reduction to 5.2, the
CEST spectrum was devoid of signal other than from the direct saturation of bulk water.
Oxidization of 5.2 to 5.1 resulted in the restoration of the original CEST signal at 55 ppm, which
is consistent with the reversibility observed in the emission spectra. Magnetization-transfer ratio
asymmetry analyses (MTRasym) revealed the net asymmetry between upfield and downfield
regions of the CEST spectra (inset of Figure 5.8). The MTRasym for 5.1 and 5.2 revealed
asymmetries of 22 and 0%, respectively. The lack of CEST contrast for 5.2 is likely due to the
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ability of the EuII ion to shorten the T1 of nearby protons resulting in the complete quenching of
saturation transfer effects. CEST modulation was recently reported using silica nanoparticle-,209
p-nitrophenylamide-,200 N-methylquinolinium-,196 and nitrone-functionalized68 analogues of 5.1
in which a change in proton- or water-exchange rate or the presence of unpaired electrons on the
ligand resulted in diminished CEST contrast. These results, however, demonstrate that the 2+
oxidation state of europium can suppress CEST contrast below a detectable threshold (inset of
Figure 5.8) and that oxidation to the 3+ oxidation state results in the recovery of the original
CEST signal. Furthermore, the complete recovery of the CEST signal, which is specific to 5.1,
indicates that dissociation of europium ions did not occur during or after the electron transfer
events.

Figure 5.8. CEST spectra (pH 7.4) and MTRasym plots (inset) of 5.1 (– –), 5.2 (—), and 5.1 after
oxidation of 5.2 by exposure to air (· ·).
Before performing phantom imaging experiments, the relaxivity (r1) of 5.1 and 5.2 were
measured using inversion recovery experiments. 5.1 did not display T1 shortening at imagingrelevant concentrations, while the relaxivity (1.4 T, 37 °C) of 5.2 was 3.72 ± 0.04 mM–1 s–1. The
lack of detectable relaxivity for 5.1 is expected because, despite EuIII exhibiting a small amount
of paramagnetic behavior at 37 °C from thermally accessible excited states, the anisotropic
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nature of the 3+ oxidation state is not conducive with expediting the relaxation of nearby
nuclei.24 The 2+ oxidation state of europium is isotropic. Accordingly, the relatively efficient
relaxation of proton nuclei is expected. The relaxivity of 5.2 is similar to clinically approved
GdIII-containing contrast agents, but lack of positive contrast enhancement for 5.1 demonstrates
the lack of T1 shortening by the anisotropic 3+ oxidation state of Eu.
5.3.4 CEST and T1-weighted imaging of EuIII/II-DOTA-4AmC at 7 T. To visualize the
responsive behavior of 5.1 and 5.2, T1-weighted and CEST phantom images (7 T, ambient
temperature) were acquired. The T1-weighted image revealed positive contrast enhancement only
from 5.2, but not from 5.1, 5.1 after oxidation of 5.2, or water (Figure 5.9). The CEST difference
image (colored red) revealed CEST contrast from 5.1 and 5.1 from the oxidation of 5.2. 5.2 and
water exhibited no CEST contrast. These images are consistent with observations regarding the
formation of 5.2 and its ability to completely quench CEST effects. The images in Figure 5.9
demonstrate the ability to provide selective suppression of T1 shortening or CEST contrast with
the EuIII/II couple.

Figure 5.9. (A) T1-weighted image and (B) CEST difference image (55 ppm image subtracted
from the –55 ppm image) of 5 mm diameter NMR tubes containing (1) 5.1, (2) 5.2, (3) 5.1 after
oxidation of 5.2, and (4) water.
While the reduction potential is negative relative to the EuII aqua ion and to the more
oxidatively stable EuII-containing cryptates,101 5.2 may be used in a similar manner to reported in
vivo studies.125 The oxygen-sensitive nature of the complex is expected to permit the
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differentiation of necrotic tissue while oxidizing elsewhere. Additionally, the transitory behavior
of EuII in vivo was described in chapter 2.194 Tissues associated with rapid clearance and high
oxygenation lead to rapid oxidation of EuII, while EuII persists in tissues with relatively slow
clearance and low oxygenation.
5.4 Conclusions
Luminescence, NMR, EPR, and UV–visible spectroscopies were used to monitor changes
in oxidation state between the commercially available contrast agent, 5.1, and its EuII analogue.
The hypersensitive emissions, reversible electrochemistry, reversible CEST signal at 55 ppm,
and stability in the presence of phosphate indicate that Eu remains chelated in both oxidation
states. The kinetic stability of 5.2 was lower than that of 5.1 but in the range of the kinetic
stabilities of clinically approved contrast agents. The assignment of 5.2 is based on rigorous
solution-phase characterization and use of 5.1 as the starting material. These data does not
provide insight into the coordination number or geometry of 5.2, but it does unambiguously
defend the assignment of a complex with a molecular form that can be described as 5.2. This
report highlights the unique magnetic and spectroscopic properties of the 3+ and 2+ oxidation
states of Eu within the ligand framework of DOTA-4AmC. These results are expected to be
applicable to a wide range of chemists interested in expanding the scope of lanthanide redox
chemistry.
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS
Conclusions
The EuII/III redox couple is an ideal platform from which redox-responsive complexes can
be designed. The change in electronic configuration from 4f7 to 4f6 causes large differences in
magnetic and spectroscopic properties between the 2+ and 3+ oxidation states of europium. For
EuII, the 4f7 ground state configuration is isotropic (L = 0), paramagnetic (µeff ≈ 7.9 Bohr
magnetons), and has low-lying 4f65d1 excited states that permit f–d transitions with UV–visible
light. For EuIII, the 4f6 ground state configuration is anisotropic (L = 3), diamagnetic (µeff = 0),
and displays typical LnIII luminescence arising from f–f transitions. From these examples it
becomes clear that one electron drastically alters the properties of the 2+ and 3+ oxidation states
of europium, where EuII exhibits positive contrast enhancement and EuIII does not. This thesis
describes research that capitalizes on the change in magnetic properties between these two
oxidation states using a variety of ligand frameworks and techniques. The ability to differentiate
europium oxidation states in response to redox stimuli has implications in detecting diseased
tissue. This thesis also describes the first report of a divalent lanthanide in vivo, which motivates
further studies.
The use of T1-weighted MRI, CEST imaging, and NMR spectroscopy demonstrated that
positive contrast enhancement was rapidly lost upon exposing EuII-containing complexes to
molecular oxygen within air while CEST can be used to detect the complex after oxidation. The
demonstration of EuII-based oxidation response represented a new avenue for responsive contrast
agents. However, at the onset of this doctoral work, nothing was known regarding the behavior
of EuII in vivo including practical routes of administration. In chapter 2, the transitory behavior
of EuII was described after intravenous, intraperitoneal, and subcutaneous injections. The
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longevity of positive contrast enhancement directly correlated with tissue oxygenation and rates
of diffusion. These data demonstrated that EuII-based positive contrast enhancement is sensitive
to the route of administration.
In chapter 3, the loss of EuII-based positive contrast enhancement to differentiate necrotic
from non-necrotic tissue in a mammary carcinoma model was described. Histological staining
revealed a correlation between specific regions of the tumor that contained Eu II that were also
necrotic. Oxygen deprivation in necrotic tissue allowed EuII to persist in necrotic regions of the
tumor while oxidizing and clearing elsewhere. The loss of positive contrast enhancement
coincided with the loss of europium from the tumor itself, but it was not clear whether or not
oxidation and clearance occurred simultaneously or sequentially. Regardless, the ability of Eu II
to differentiate necrotic tumor tissue was demonstrated.
In chapter 4, the combination of EuII-based positive contrast enhancement with CEST
was described. CEST at 1.2 ppm was observed before and after oxidation likely due to exchange
between hydroxyl protons of cholesterol within the lipid bilayer. Dynamic light scattering was
used to determine that size and polydispersity of the liposomes were unchanged by oxidation of
EuII, indicating that the liposome membrane was not damaged. While these results demonstrated
that positive contrast enhancement and CEST could be coupled to enable indirect detection of
EuIII after oxidation, the CEST signal at 1.2 ppm was not ideal because of the proximity to the
bulk water proton resonance.
In chapter 5, the reduction of a well characterized, commercially available EuIIIcontaining poly(amino glycinate) complex with Zn dust was described. The reduction potential
of the complex was measured at pH 4 and 7 using cyclic voltammetry. The similarity in
reduction potential at both pH values indicated the electron transfer process was not proton
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coupled. Changes in oxidation state were monitored using luminenesnce, EPR, UV–visible, and
NMR spectroscopies. These data, coupled with the lack of precipitation in the presence of
phosphate, strongly indicated that EuII remained chelated during electron transfer processes.
Furthermore, an acid-catalyzed dissociation experiment was used to measure the kinetic stability
of the EuII-containing complex, which was in the range of clinically approved Gd III-containing
complexes. The reversibility of the complex was demonstrated using T1-weighted and CEST
imaging in which the 2+ oxidation state produced positive contrast enhancement and no CEST
effect, while the 3+ oxidation state produced CEST effect and no observable positive contrast
enhancement.
Future Directions
The kinetic stability of a EuII/III-containing complex is important. While dissociation of
EuIII from cryptates can be addressed by liposome encapsulation, this route is limited by timeintensive purification. The ability of the poly(amino glycinate) complex in chapter 5 to be
kinetically stable with europium in both oxidation states is a promising direction to avoid issues
associated with dissociation of the complex. Additionally, starting with kinetically stable Eu IIIcontaining complexes ensures that the 3+ oxidation state is stable. Therefore, when considering a
new EuII-containing complex for responsive MRI, whether it be a cryptate or cyclen-based
macrocyclic complex, it is advisable to consider the kinetic stability of its Eu III-containing
analogue. For new complexes, this will involve measuring the kinetic stability and comparing to
relatively kinetically stable complexes under identical conditions.
Complexes combining functional groups conducive to kinetic (carboxylate and amide)
and oxidative (polyether, polythioether, and thiol) stability can be envisioned to balance these
stabilities. If the donor atoms are primarily carboxylate or amide oxygens, the kinetic and
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oxidative stabilities are expected to increase and decrease, respectively. If the donor atoms are
primarily polyether, polythioether, or thiols, the kinetic and oxidative stabilities are expected to
decrease and increase, respectively. Complexes with a mixture of these functional groups are
expected to have moderate kinetic and oxidative stability. However, the payoff in increased
oxidative stability must outweigh the limitation of decreased kinetic stability because, as of now,
all EuII-containing complexes are prone to oxidation in air. Accordingly, given that all EuIIcontaining complexes are oxidized by air, kinetic stability should be the top priority. If a EuIIcontaining complex can be made air-stable for even a relatively short amount of time, such as
hours with negligible oxidation, a loss in kinetic stability would be justified.
While EuII-based positive contrast enhancement was informative during in vivo studies,
the species responsible for oxidizing EuII are currently unknown. One of the most likely
contributors to oxidation is molecular oxygen, but the scope of biologically relevant oxidants
capable of oxidizing EuII-containing complexes is not known. Potential oxidants worth exploring
include nitric oxide, hydrogen peroxide, bromate, and oxidized glutathione. Measuring the rate
of oxidation can be accomplished using UV–visible absorptions specific to EuII. The rate of
oxidation can be viewed as a function of the Eu II reduction potential, oxidant strength, and pH.
These apparent thermodynamic driving forces and oxidation kinetics will shed light on the nature
of EuII oxidation chemistry.
In addition to uncovering oxidants capable of reacting with EuII, the products of oxidation
are equally important from a toxicity standpoint. Assuming the complex itself does not dissociate
to release EuIII, the species it reduced may or may not be toxic depending on its location and
concentration. A likely product of the reaction between EuII and molecular oxygen is superoxide.
Furthermore, if hydrogen peroxide is an intermediate in the reduction of oxygen to water, it is
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possible that EuII could react with hydrogen peroxide resembling Fenton chemistry to generate
hydroxyl radical and hydroxide.
At first glance, the potential formation of superoxide or hydroxyl radicals in vivo does not
necessarily bode well for EuII-containing complexes. However, this chemistry may be exploited
through direct injections described in chapters 2 and 3 of this thesis. Specifically in chapter 3
where intratumoral injections were described, the effect of EuII oxidation within tumor tissue was
not explored. If the majority of EuII oxidized in tumor tissue, it may have generated reactive
oxygen species such as superoxide. A bolus of superoxide might damage tissue near the site of
injection where oxidation of EuII occurs. Perhaps the oxidation of EuII could be used for
therapeutic purposes when directly injected into tumors. The most promising path forward for
such a project would involve the poly(amino glycinate) complex of chapter 5 because of its
robust kinetic stability in both oxidation states of europium and the ability to detect positive
contrast or CEST depending on the oxidation state of europium. This experiment would involve
the mammary carcinoma model described in chapter 3, where the size of the tumor can be
monitored as a function of time using caliper measurements. Tumor growth could be compared
between mice that received intratumoral injections of the EuII-containing complex, the EuIIIcontaining complex, and a phosphate-buffered saline blank. The hypothesis would be that if the
oxidation of EuII inside of tumors produces reactive oxygen species, then the tumor growth will
be diminished when injected with the EuII-containing complex when compared to the control
injections. Furthermore, MRI could be used to observe the behavior of the poly(amino glycinate)
complex after intratumoral injection. Even if the growth of tumors is not diminished,
fundamental information would be uncovered that might guide the path forward for Eu IIcontaining complexes for responsive MRI.
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APPENDIX A
1H-

AND 13C- NMR SPECTRA

3.2

Figure A1. 1H-NMR spectrum of 3.2.
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3.2

Figure A2. 13C-NMR spectrum of 3.2.
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3.3

Figure A3. 1H-NMR spectrum of 3.3.
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3.3

Figure A4. 13C-NMR spectrum of 3.3.
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3.4

Figure A5. 1H-NMR spectrum of 3.4.
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3.4

Figure A6. 13C-NMR spectrum of 3.4.
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3.5

Figure A7. 1H-NMR spectrum of 3.5.
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3.5

Figure A8. 13C-NMR spectrum of 3.5.
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APPENDIX B
Crystallography Data for Complex 3.6
Table B1. Data collection and structure refinement for 3.6.
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Coverage of independent reflections
Absorption correction
Refinement method
Refinement program
Function minimized
Data / restraints / parameters
Goodness-of-fit on F2
Δ/σmax
Final R indices

Weighting scheme
Largest diff. peak and hole
R.M.S. deviation from mean

1.89 to 37.04°
–17 ≤ h ≤ 17, –30 ≤ k ≤ 30, –23 ≤ l ≤ 23
146813
12933 [R(int) = 0.0381]
99.0%
multi-scan
Full-matrix least-squares on F2
SHELXL-2014/7 (Sheldrick, 2014)
Σ w(Fo2 – Fc2)2
12933 / 0 / 307
1.044
0.004
10835 data;
R1 = 0.0248, wR2 = 0.0582
I>2σ(I)
all data
R1 = 0.0348, wR2 = 0.0615
2
2
w = 1/[σ (Fo ) + (0.0287P)2 + 1.8719P]
where P = (Fo2 + 2Fc2)/3
3.469 and –1.129 eÅ–3
0.120 eÅ–3

Table B2. Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for
3.6.
Eu1
Cl00
Cl1
F1
O1
O2
O3
O4
O5
O6
N1
N2
C1
C2
C3
C4

x/a
0.72371(2)
0.85158(4)
0.71290(4)
0.72587(16)
0.89236(11)
0.64902(11)
0.55957(11)
0.79636(11)
0.59323(11)
0.85365(11)
0.98346(12)
0.46156(13)
0.04613(15)
0.02606(16)
0.85758(17)
0.73581(17)

y/b
0.88852(2)
0.14111(2)
0.03621(2)
0.86595(13)
0.86458(8)
0.84955(7)
0.92393(7)
0.93805(7)
0.76285(6)
0.77825(6)
0.91368(8)
0.88466(7)
0.93161(10)
0.87158(11)
0.80576(10)
0.82887(11)

z/c
0.80721(2)
0.48492(3)
0.87236(3)
0.29102(11)
0.96842(9)
0.97661(8)
0.63940(8)
0.63314(8)
0.75252(9)
0.74146(9)
0.79521(10)
0.81690(10)
0.89633(12)
0.97026(13)
0.02992(13)
0.06290(12)

U(eq)
0.00950(2)
0.01885(7)
0.01922(7)
0.0559(5)
0.0191(2)
0.0162(2)
0.0161(2)
0.0173(2)
0.0158(2)
0.0159(2)
0.0141(2)
0.0148(2)
0.0193(3)
0.0201(3)
0.0213(3)
0.0208(3)
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C5
C6
C7
C8
C9
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22

0.52310(16)
0.45400(16)
0.40528(15)
0.42418(15)
0.59385(16)
0.5098(2)
0.5574(2)
0.6852(3)
0.7719(2)
0.72431(16)
0.92157(15)
0.98334(15)
0.40019(15)
0.49404(15)
0.67432(16)
0.77504(15)
0.95770(15)
0.04719(15)

0.86173(11)
0.91150(10)
0.94224(9)
0.92592(10)
0.90965(9)
0.88917(10)
0.87445(12)
0.88084(13)
0.90231(12)
0.91724(10)
0.96867(10)
0.98154(9)
0.81081(9)
0.74648(9)
0.69958(9)
0.72189(9)
0.79704(9)
0.84970(9)

0.99722(13)
0.91777(13)
0.74564(13)
0.64135(13)
0.54876(12)
0.46459(13)
0.37704(15)
0.37640(14)
0.45878(13)
0.54551(11)
0.62833(12)
0.73384(13)
0.79683(13)
0.80951(13)
0.74779(13)
0.68785(12)
0.69101(12)
0.75482(12)

Table B3. Bond lengths (Å) for 3.6.
Eu1-O6
Eu1-O2
Eu1-O3
Eu1-Cl1
Eu1-N1
O1-C2
O2-C5
O3-C9
O4-C14
O5-C19
O6-C21
N1-C1
N1-C22
N2-C7
C1-C2
C1-H1
C2-H35
C3-H4
C4-H33
C5-C6
C5-H5
C6-H29
C7-H6
C8-H15

2.6432(11)
2.6576(11)
2.7304(11)
2.7931(4)
2.8269(13)
1.423(2)
1.427(2)
1.370(2)
1.369(2)
1.4288(19)
1.4322(19)
1.473(2)
1.479(2)
1.477(2)
1.512(2)
0.99
0.99
0.99
0.99
1.503(3)
0.99
0.99
0.99
0.99

Eu1-O1
Eu1-O5
Eu1-O4
Eu1-N2
F1-C12
O1-C3
O2-C4
O3-C8
O4-C15
O5-C18
O6-C20
N1-C16
N2-C6
N2-C17
C1-H2
C2-H34
C3-C4
C3-H3
C4-H32
C5-H31
C6-H30
C7-C8
C7-H16
C8-H14

2.6490(12)
2.6827(11)
2.7616(11)
2.8107(14)
1.334(2)
1.430(2)
1.4278(19)
1.444(2)
1.450(2)
1.4362(19)
1.4342(19)
1.474(2)
1.475(2)
1.478(2)
0.99
0.99
1.494(3)
0.99
0.99
0.99
0.99
1.500(2)
0.99
0.99

0.0206(3)
0.0195(3)
0.0182(3)
0.0190(3)
0.0172(3)
0.0243(3)
0.0329(5)
0.0342(5)
0.0259(4)
0.0178(3)
0.0190(3)
0.0181(3)
0.0182(3)
0.0173(3)
0.0175(3)
0.0182(3)
0.0173(3)
0.0168(3)
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C9-C10
C10-C11
C11-C12
C12-C13
C13-H8
C15-H12
C16-H9
C17-C18
C17-H28
C18-H27
C19-H25
C20-H24
C21-C22
C21-H22
C22-H20

1.391(2)
1.397(3)
1.364(4)
1.393(3)
0.95
0.99
0.99
1.514(2)
0.99
0.99
0.99
0.99
1.513(2)
0.99
0.99

C9-C14
C10-H13
C11-H7
C13-C14
C15-C16
C15-H11
C16-H10
C17-H17
C18-H26
C19-C20
C19-H18
C20-H23
C21-H21
C22-H19

1.401(2)
0.95
0.95
1.386(2)
1.506(2)
0.99
0.99
0.99
0.99
1.501(2)
0.99
0.99
0.99
0.99

Table B4. Bond angles (°) for 3.6.
O6-Eu1-O1
O1-Eu1-O2
O1-Eu1-O5
O6-Eu1-O3
O2-Eu1-O3
O6-Eu1-O4
O2-Eu1-O4
O3-Eu1-O4
O1-Eu1-Cl1
O5-Eu1-Cl1
O4-Eu1-Cl1
O1-Eu1-N2
O5-Eu1-N2
O4-Eu1-N2
O6-Eu1-N1
O2-Eu1-N1
O3-Eu1-N1
Cl1-Eu1-N1
C2-O1-C3
C3-O1-Eu1
C5-O2-Eu1
C9-O3-C8
C8-O3-Eu1
C14-O4-Eu1
C19-O5-C18
C18-O5-Eu1
C21-O6-Eu1

80.89(4)
59.17(4)
110.46(4)
100.69(4)
123.71(4)
73.36(4)
176.40(4)
55.18(3)
86.75(3)
146.53(3)
90.20(3)
120.19(4)
61.31(4)
117.51(4)
62.07(4)
121.36(4)
114.52(4)
87.58(3)
113.82(13)
113.87(9)
123.38(9)
115.39(12)
119.81(9)
118.33(10)
111.28(12)
114.22(9)
118.25(9)

O6-Eu1-O2
O6-Eu1-O5
O2-Eu1-O5
O1-Eu1-O3
O5-Eu1-O3
O1-Eu1-O4
O5-Eu1-O4
O6-Eu1-Cl1
O2-Eu1-Cl1
O3-Eu1-Cl1
O6-Eu1-N2
O2-Eu1-N2
O3-Eu1-N2
Cl1-Eu1-N2
O1-Eu1-N1
O5-Eu1-N1
O4-Eu1-N1
N2-Eu1-N1
C2-O1-Eu1
C5-O2-C4
C4-O2-Eu1
C9-O3-Eu1
C14-O4-C15
C15-O4-Eu1
C19-O5-Eu1
C21-O6-C20
C20-O6-Eu1

110.19(4)
63.65(4)
79.16(4)
175.37(4)
74.07(4)
121.69(4)
103.29(4)
149.60(3)
86.35(3)
89.80(3)
124.92(4)
61.21(4)
62.50(4)
85.26(3)
62.28(4)
125.70(4)
59.42(4)
172.22(4)
122.94(10)
112.35(12)
123.09(9)
119.48(9)
117.00(13)
122.88(9)
112.68(9)
110.48(12)
113.81(9)
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C1-N1-C16
C16-N1-C22
C16-N1-Eu1
C6-N2-C7
C7-N2-C17
C7-N2-Eu1
N1-C1-C2
C2-C1-H2
C2-C1-H1
O1-C2-C1
C1-C2-H34
C1-C2-H35
O1-C3-C4
C4-C3-H4
C4-C3-H3
O2-C4-C3
C3-C4-H33
C3-C4-H32
O2-C5-C6
C6-C5-H31
C6-C5-H5
N2-C6-C5
C5-C6-H30
C5-C6-H29
N2-C7-C8
C8-C7-H6
C8-C7-H16
O3-C8-C7
C7-C8-H15
C7-C8-H14
O3-C9-C10
C10-C9-C14
C9-C10-H13
C12-C11-C10
C10-C11-H7
F1-C12-C13
C14-C13-C12
C12-C13-H8
O4-C14-C9
O4-C15-C16
C16-C15-H12
C16-C15-H11
N1-C16-C15
C15-C16-H9
C15-C16-H10

108.41(13)
112.47(13)
104.49(9)
108.36(13)
112.19(13)
104.68(9)
112.54(14)
109.1
109.1
107.22(13)
110.3
110.3
106.90(14)
110.3
110.3
107.43(13)
110.2
110.2
108.31(13)
110.0
110.0
113.07(14)
109.0
109.0
113.04(14)
109.0
109.0
107.76(13)
110.2
110.2
124.80(16)
120.62(16)
120.4
119.01(19)
120.5
120.0(2)
117.5(2)
121.2
114.76(14)
106.21(12)
110.5
110.5
112.42(14)
109.1
109.1

C1-N1-C22
C1-N1-Eu1
C22-N1-Eu1
C6-N2-C17
C6-N2-Eu1
C17-N2-Eu1
N1-C1-H2
N1-C1-H1
H2-C1-H1
O1-C2-H34
O1-C2-H35
H34-C2-H35
O1-C3-H4
O1-C3-H3
H4-C3-H3
O2-C4-H33
O2-C4-H32
H33-C4-H32
O2-C5-H31
O2-C5-H5
H31-C5-H5
N2-C6-H30
N2-C6-H29
H30-C6-H29
N2-C7-H6
N2-C7-H16
H6-C7-H16
O3-C8-H15
O3-C8-H14
H15-C8-H14
O3-C9-C14
C9-C10-C11
C11-C10-H13
C12-C11-H7
F1-C12-C11
C11-C12-C13
C14-C13-H8
O4-C14-C13
C13-C14-C9
O4-C15-H12
O4-C15-H11
H12-C15-H11
N1-C16-H9
N1-C16-H10
H9-C16-H10

110.65(13)
106.36(9)
114.04(9)
112.12(13)
103.66(9)
115.14(9)
109.1
109.1
107.8
110.3
110.3
108.5
110.3
110.3
108.6
110.2
110.2
108.5
110.0
110.0
108.4
109.0
109.0
107.8
109.0
109.0
107.8
110.2
110.2
108.5
114.58(14)
119.2(2)
120.4
120.5
116.7(2)
123.39(19)
121.2
124.95(16)
120.27(16)
110.5
110.5
108.7
109.1
109.1
107.9
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N2-C17-C18
C18-C17-H17
C18-C17-H28
O5-C18-C17
C17-C18-H26
C17-C18-H27
O5-C19-C20
C20-C19-H25
C20-C19-H18
O6-C20-C19
C19-C20-H24
C19-C20-H23
O6-C21-C22
C22-C21-H21
C22-C21-H22
N1-C22-C21
C21-C22-H19
C21-C22-H20

113.13(13)
109.0
109.0
108.05(13)
110.1
110.1
107.56(13)
110.2
110.2
108.38(13)
110.0
110.0
109.30(13)
109.8
109.8
114.37(13)
108.7
108.7

N2-C17-H17
N2-C17-H28
H17-C17-H28
O5-C18-H26
O5-C18-H27
H26-C18-H27
O5-C19-H25
O5-C19-H18
H25-C19-H18
O6-C20-H24
O6-C20-H23
H24-C20-H23
O6-C21-H21
O6-C21-H22
H21-C21-H22
N1-C22-H19
N1-C22-H20
H19-C22-H20

109.0
109.0
107.8
110.1
110.1
108.4
110.2
110.2
108.5
110.0
110.0
108.4
109.8
109.8
108.3
108.7
108.7
107.6

Table B5. Anisotropic atomic displacement parameters (Å2) for 3.6.
U11
Eu1 0.00922(3)
Cl00 0.01749(16)
Cl1 0.02206(17)
F1
0.0571(11)
O1
0.0136(5)
O2
0.0162(5)
O3
0.0129(5)
O4
0.0142(5)
O5
0.0148(5)
O6
0.0156(5)
N1
0.0125(5)
N2
0.0122(5)
C1
0.0139(6)
C2
0.0136(6)
C3
0.0210(7)
C4
0.0251(8)
C5
0.0208(7)
C6
0.0175(7)
C7
0.0122(6)
C8
0.0127(6)
C9
0.0225(7)
C10 0.0316(9)
C11 0.0507(13)

U22
0.00950(3)
0.02056(17)
0.01122(14)
0.0865(13)
0.0241(6)
0.0205(5)
0.0217(5)
0.0254(6)
0.0121(5)
0.0143(5)
0.0148(5)
0.0154(6)
0.0237(8)
0.0282(8)
0.0231(8)
0.0257(8)
0.0249(8)
0.0222(7)
0.0182(7)
0.0224(8)
0.0154(6)
0.0217(8)
0.0302(10)

U33
0.00978(3)
0.01868(16)
0.02576(18)
0.0256(7)
0.0187(5)
0.0125(4)
0.0130(5)
0.0126(5)
0.0212(5)
0.0191(5)
0.0151(5)
0.0172(6)
0.0193(7)
0.0170(7)
0.0183(7)
0.0108(6)
0.0183(7)
0.0208(7)
0.0240(7)
0.0207(7)
0.0128(6)
0.0170(7)
0.0156(8)

U23
-0.00072(2)
-0.00237(14)
-0.00374(13)
-0.0112(8)
0.0084(5)
0.0014(4)
0.0006(4)
0.0029(4)
0.0003(4)
-0.0043(4)
-0.0001(4)
0.0011(5)
-0.0027(6)
0.0012(6)
0.0080(6)
0.0036(6)
0.0005(6)
-0.0005(6)
0.0038(6)
0.0049(6)
-0.0001(5)
-0.0015(6)
-0.0054(7)

U13
0.00156(2)
0.00335(12)
0.00810(14)
0.0111(7)
-0.0007(4)
0.0038(4)
0.0002(4)
0.0037(4)
0.0047(4)
0.0066(4)
0.0024(4)
0.0033(4)
-0.0001(5)
-0.0021(5)
-0.0014(6)
0.0011(5)
0.0104(6)
0.0090(6)
0.0026(5)
-0.0013(5)
-0.0004(5)
-0.0048(6)
-0.0020(8)

U12
0.00028(2)
0.00031(13)
-0.00116(12)
0.0158(9)
-0.0011(4)
0.0006(4)
0.0006(4)
0.0014(4)
-0.0008(4)
-0.0016(4)
0.0001(4)
0.0006(4)
-0.0055(5)
-0.0006(6)
-0.0011(6)
-0.0018(6)
0.0004(6)
0.0031(6)
0.0029(5)
-0.0004(5)
0.0019(5)
-0.0020(7)
0.0032(9)
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C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22

0.0558(14)
0.0324(9)
0.0233(7)
0.0169(7)
0.0154(6)
0.0127(6)
0.0152(6)
0.0187(7)
0.0214(7)
0.0174(7)
0.0127(6)

0.0339(11)
0.0317(9)
0.0188(7)
0.0217(7)
0.0157(7)
0.0189(7)
0.0140(6)
0.0112(6)
0.0137(6)
0.0168(7)
0.0175(7)

0.0131(7)
0.0148(7)
0.0114(6)
0.0202(7)
0.0240(7)
0.0232(7)
0.0227(7)
0.0228(7)
0.0200(7)
0.0193(7)
0.0210(7)

-0.0034(7)
0.0024(6)
0.0017(5)
0.0067(6)
0.0027(6)
0.0020(6)
0.0017(5)
-0.0023(5)
-0.0063(5)
-0.0011(5)
0.0012(5)

0.0058(8)
0.0076(6)
0.0029(5)
0.0080(5)
0.0060(5)
0.0035(5)
0.0035(5)
0.0035(5)
0.0047(6)
0.0081(5)
0.0047(5)

0.0125(9)
0.0116(7)
0.0058(6)
0.0026(6)
-0.0017(5)
-0.0017(5)
-0.0039(5)
-0.0004(5)
-0.0008(5)
0.0022(5)
0.0029(5)

Table B6. Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) for
3.6.
H2
H1
H34
H35
H4
H3
H33
H32
H31
H5
H30
H29
H6
H16
H15
H14
H13
H7
H8
H12
H11
H9
H10
H17
H28
H26
H27
H25
H18

x/a
1.0122
1.1387
1.0623
1.0684
0.9250
0.8457
0.7005
0.7509
0.5266
0.4778
0.3633
0.4906
0.4441
0.3128
0.3851
0.3835
0.4211
0.5017
0.8602
0.9143
0.9725
1.0723
0.9373
0.3535
0.3372
0.5306
0.4505
0.6245
0.7140

y/b
0.9797
0.9380
0.8235
0.8858
0.7983
0.7583
0.7869
0.8718
0.8858
0.8134
0.9148
0.9625
0.9913
0.9459
0.8772
0.9653
0.8853
0.8602
0.9066
1.0163
0.9331
0.9983
1.0220
0.8103
0.8034
0.7405
0.6993
0.6568
0.6845

z/c
0.9171
0.8963
0.9521
1.0374
1.0878
0.9923
1.0974
1.1091
1.0628
0.9982
0.9262
0.9258
0.7658
0.7480
0.6196
0.5962
0.4666
0.3188
0.4557
0.5910
0.5952
0.7346
0.7629
0.7283
0.8422
0.8802
0.7861
0.7162
0.8152

U(eq)
0.023
0.023
0.024
0.024
0.026
0.026
0.025
0.025
0.025
0.025
0.023
0.023
0.022
0.022
0.023
0.023
0.029
0.04
0.031
0.023
0.023
0.022
0.022
0.022
0.022
0.021
0.021
0.021
0.021
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H24
H23
H21
H22
H19
H20

0.8274
0.7349
0.9250
1.0039
1.0946
1.1101

0.6779
0.7417
0.8213
0.7510
0.8209
0.8693

0.6764
0.6228
0.6270
0.6774
0.8107
0.7150

0.022
0.022
0.021
0.021
0.02
0.02
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The research projects described in this dissertation are focused on studying the oxidation
of EuII-containing complexes within the context of responsive MRI. Prior to this research, Eu II
had not been explored within the context of oxidation-responsive MRI nor had the use of this ion
been reported in vivo. The results of these studies enable predictions about the oxidationresponsive behavior of EuII-containing complexes in vitro and in vivo.
The EuII-containing cryptate 1.33 was used to evaluate EuII-based positive contrast
enhancement after intravenous, intraperitoneal, and subcutaneous injections. The transitory
behavior of the positive contrast enhancement correlated with reported levels of oxygenation and
rates of diffusion. Additionally, europium was observed to clear primarily through the liver and
kidneys with no observable adverse side effects.
The EuII-containing cryptate 3.6 was synthesized and characterized in the solid and
solution phases. While a chloride counterion was coordinated in the solid state, conductivity and
17

O-NMR experiments strongly suggested chloride counterions were dissociated in aqueous

solution. EuII-based positive contrast enhancement persisted in a mammary carcinoma model for

168

at least 3 hours after intratumoral injection. Additionally, EuII-based positive contrast
enhancement persisted specifically in necrotic regions of the tumor as evidenced by histological
staining.
The EuII-containing complex 1.33 was encapsulated inside of liposomes with an average
diameter of 110 nm. Positive contrast enhancement and CEST were observed before oxidation of
1.33, but only CEST was observed after oxidation of 1.33 by molecular oxygen in the air. CEST
effect was likely caused by the exchange of hydroxyl protons on cholesterol or water molecules
associated with the outer phospholipid bilayer. This project demonstrated the feasibility of
encapsulating air-sensitive EuII-containing complexes in liposomes and the ability to combine
positive contrast enhancement with CEST.
The commercially available EuIII-containing complex 5.1 was reduced with Zn dust to
produce its EuII-containing analogue 5.2. Changes in oxidation state were monitored using
luminescence, EPR, UV–visible, and

1

H-NMR spectroscopies. Collectively, all of the

experiments indicated that europium remained chelated upon reduction to the 2+ oxidation state
and oxidation back to the 3+ oxidation state. While the poly(amino glycinate) ligand caused the
EuII/III redox couple to be approximately –0.9 V vs Ag/AgCl, the kinetic stability of the complex
in the 2+ oxidation state was within the range of clinically approved contrast agents. Only
positive contrast enhancement was observed when EuII was present, and only CEST was
observed when EuIII was present.
The ability to essentially disable positive contrast enhancement through the oxidation of
EuII holds great potential for responsive MRI. The balance of oxidative and kinetic stability will
yield fundamental information regarding the EuII/III redox couple and coordination environment.
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